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BRE is a broad-spectrum anti-apoptotic protein, which attenuates both extrinsic and intrinsic 
apoptosis. However, the molecular and biochemical mechanisms by which BRE inhibits 
apoptosis remain completely unknown. Here I provide evidence that BRE attenuates 
apoptosis through maintaining the cellular level of XIAP, which is a potent endogenous 
inhibitor of caspases functioning in intrinsic and extrinsic pathways.  
 
Using a mouse Lewis lung carcinoma cell line D122, we found that shRNA-mediated stable 
depletion of BRE rendered the cells susceptible to TNF-α-induced apoptosis even in the 
absence of cycloheximide (CHX). CHX plays a critical pro-apoptotic role by inhibiting 
synthesis of anti-apoptotic proteins, which TNF-α also up-regulates through activation of 
NF-κB pathway. Western blot analysis of the NF-κB-driven and CHX-sensitive anti-apoptotic 
proteins revealed only XIAP, but not cIAP-1, cIAP-2, or cFLIP, was down-regulated in 
BRE-depleted cells. Reconstitution of the BRE-depleted mouse cells with highly homologous 
human BRE restored the XIAP protein level, confirming a positive regulatory role of BRE on 
XIAP protein expression. Furthermore, reconstitution of the BRE-depleted cells with human 
BRE or XIAP rendered the cells less sensitive to TNF-α-induced apoptosis. 
 
Addition of NEM (N-Ethylmaleimide), which binds irreversibly to cysteine residues of 
proteins, to cell lysates, was found to abrogate, the recognition of BRE by our anti-BRE 
antibody (Mab489-7) in Western blot analysis. Correspondingly, XIAP level was also found 
reduced in cell lysates. This correlation provides in vitro evidence that BRE has a protective 
role for XIAP, and that this role is related to cysteine residues of BRE.  
 
I have shown that that XIAP is not only cleaved by caspases during apoptosis, but also 
subjected to proteaosomal degradation, indicating that ubiquitination of XIAP is an important 
regulatory mechanism for the stability of this protein. As BRE is known to contain 
polyubiquitin-binding domains and forms complexes with deubiquitination activity, the issue 
of whether BRE could remove the ubiquitination of XIAP was investigated. I found that 
over-expressed XIAP underwent K48-linked, K63-linked, and K0-linked polyubiquitination, 
respectively. Overexpression of BRE led to the removal of or inhibited K0- but not K48- or 
K63-linked ubiquitination of XIAP. 
 
Taken together, I have provided evidence that BRE exerts its anti-apoptotic function through 
maintaining the cellular level of XIAP, a potent endogenous inhibitor of apoptosis. Promoting 
removal of linear ubiquitin chain of XIAP, or inhibition of the chain formation to prevent 
linear polyubiquitin-mediated proteasomal degradation of XIAP may be the mechanism by 
ii 
which BRE stabilizes this protein. Whether such interaction between BRE and XIAP is direct 
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CHAPTER 1: Introduction 
1.1 Apoptosis 
1.1.1 Overview of apoptosis 
The original meaning of apoptosis is the falling of leaves from a tree. This ancient Greek 
word was used to describe the morphological characters of the energy used process of 
formation of ‘apoptotic bodies’ from a cell by John Kerr first (1). The morphological changes 
of apoptosis comprise cellular shrinkage, membrane blebbing, nuclear condensation, 
chromatin condensation, DNA fragmentation, and permeabilization of mitochondria (2). 
Abnormality of apoptosis generates pathological consequences, such as cancer, 
neurodegenerative and autoimmune diseases (3).  
 
Apoptosis can be divided into three main stages: induction, effector, and degradation. The 
induction stage involves the initiation and activation of procaspase cascades. Alteration of 
mitochondrial membrane permeability, and release of proteins and proteases from 
mitochondria into cytosol form the effector stage (4). Degradation stage involves cleavage of 
cellular proteins and disintegration of internucleosomal DNA. 
 
1.1.2 Caspases 
Caspases, which are the well-conserved and efficient cysteinyl aspartate-specific proteases, 
play a central role in the execution of apoptosis (5). Caspases are produced by cells as 
catalytically inactive zymogens which undergo proteolytic processing during activation (6). 
To date, 14 caspases have been found,which can be sub-grouped into proinflammatory 
(caspases 1, 4, 5, 11, 12, 13, 14) and pro-apoptotic caspases. The latter can be subdivided 
further into initiator caspases (2, 8, 9, and 10) and effector caspases (3, 6, and 7). When cells 
are exposed to pro-apoptotic stimulus, the initiator caspases are activated first, which in turn 
activate the effector caspases to cleave cellular substrates, resulting in cell death. Many 
endogenous cellular factors regulate caspases. The IAP family proteins are the most potent 
ones among them. The characteristic domain of IAP family proteins is BIR domain. Members 
of this family contain one or more BIR domains. For example, XIAP, NAIP, cIAP-1, and 
cIAP-2 have three BIR domains each. XIAP is the most potent one in inhibiting caspases 
among all members of the IAP family. The BIR2 domain together with a short N-terminal 
flanking sequence of XIAP binds and inhibits caspase 3 and 7. The BIR3 domain of XIAP 
binds and inhibits caspase 9 (7). The activities of IAP family members can be regulated by 
some endogenous cell factors, which are released, form mitochondria. For example, the 
mitochondrial proteins Smac/DIABLO and Omi/HtrA2 can bind to XIAP and antagonize its 
inhibitory activity on caspases. Another example of the endogenous inhibitors of caspases is 
cFLIP. It has a pro-domain similar to that of procaspase-8, but lacks a caspase active site. It 
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can inhibit procaspases 8 and 10. 
 
1.1.3 Extrinsic and intrinsic apoptotic pathways 
In mammalian cells, apoptosis has been subdivided into two major pathways: extrinsic 
pathway and intrinsic pathway. The extrinsic pathway is initiated by pro-apoptotic receptor 
signals on the cellular surface. The intrinsic pathway is activated by the signals inside the cell 
itself, which involve the destruction of mitochondrial membrane integrity. The molecular 
signal transduction of these two pathways is showed in Figure 1-1 (8). 
 
The initial step of the extrinsic pathway is the binding of death receptors with their specific 
ligands. The transmembrane death receptors belong to TNF family. These receptors contain 
two important domains. One is cysteine-rich extracellular domain, which enables them to 
recognize their ligands specifically. The other is intra-cellular death domain (DD). The 80 
amino-acids-containing DD domain is crucial due to its role in transferring the death signal 
from cellular surface to the intercellular pathways. 
 
Currently, six types of death receptors have been identified. They are TNF-R1 (also called 
DR1, p55, p60, or CD120a), Fas (also called DR2, CD95, or APO-1), DR3 (also known as 
APO-3, LARD, TRAMP,or WSL1), TRAIL-R1 (also known as DR4 or APO-2), TRAIL-R2 
(DR5, KILLER, or TRICK2), and DR6 (9). After binding of transmembrane death receptors 
with their specific ligands (FasR/FasL, TNFR1/TNF-α, DR-4/TRAIL, DR-5/TRAIL, 
DR3/Apo-3L/TWEAK), the intra-cellular death domain of the death receptors binds to FADD 
or TRADD to form DISC complex with the recruitment of pro-caspase 8. Then, pro-caspase 8 
is further activated to become active caspase 8, which serves as an initiator caspase to activate 
downstream effector caspases, such as caspase 3 and 7, which in turn cleave vital substrates 
and lead to apoptosis.  
 
The intrinsic pathway, also named mitochondrial pathway, is usually activated by stimuli 
from inside the cell such as DNA damage, oxidants, ceramide, and other factors, which via a 
complex chain of events leads to mitochondrial outer membrane permeabilization (MOMP) 
and release of cytochrome c from the mitochondria. The intermembrane space of 
mitochondria contains many proteins important to cell death induction and regulation, such as 
cytochrome c (cyt c), apoptosis-inducing factors (AIF), EndoG, Omi/HtrA2, and 
Smac/DIABLO. Cytochrome c stimulates apoptosome formation after being released into 
cytoplasm. Apaf-1, dATP, cytochrome c, and caspase 9 constitute apoptosome complex. The 
caspase 9, which belongs to initiator caspases, then activates downstream effector caspases, 
such as caspases 3, 6, 7, which in turn cleave vital substrates and lead to cellular death. The 
release of cytochrome c is mainly regulated by interactions between anti-apoptotic and 
pro-apoptotic members of Bcl-2 family (10, 11). Under normal conditions, cytochrome c is 
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sequestered in the inter-membrane space of mitochondria. However, upon apoptotic 
stimulation, BAX and BAK are activated to form homo-oligomers at the outer mitochondrial 
membrane, resulting in pore formation and MOMP, during which cytochrome c exits and 
enters into the cytosol (12). Anti-apoptotic Bcl-2 family member, such as Bcl-2 prevents the 
release of cytochrome c. Bcl-2 interacts directly with BAK and BAX and inhibits their 
oligomerization (13). The pro-apoptotic member of Bcl-2 family, BID is the primary 
activators of BAX and BAK (14). Active BID, also known as truncated BID (tBID), induces 
the oligomerization of BAX and BAK (15, 16). Furthermore, tBID induces mitochondrial 
cristae remodelling that can promote the mobilization of cytochrome c (17). 
 
These two pathways do not act separately. They interact with one another, allowing 
components from one pathway to affect those of the other. For example, active caspase 8 
from extrinsic pathway cleaves BID protein into tBID, which can then bind to the 
pro-apoptotic BAX and BAK to activate intrinsic pathway via causing to MOMP and 
cytochrome c release (18). 
 
     
 
Figure 1-1. Extrinsic and intrinsic apoptosis (reproduced from reference (8)) 
 
1.2 NF-κB 
1.2.1 Overview of NF-κB 
NF-κB, a protein complex which regulates the transcription of DNA, was first discovered in 
the immunoglobulin light-chain enhancer in B cells via its interaction with an 11-base-pairs 
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sequence (19). NF-κB can be activated by many bacterial products and stimulation of a wide 
variety of cell-surface receptors. Once activated, it can change gene expression very quickly. 
It regulates the expression of many targets, which are involved in many tissues and systems. 
Its major function is involved in the immune system. Apart from that, NF-κB is closely 
related to apoptosis and cancer (20). It can promote cell survival by either up-regulating the 
activity of anti-apoptotic genes or down-regulating the activity of apoptotic genes. The 
anti-apoptotic target genes of NF-κB include Survivin, MnSOD, CyclinD1, γGCS, cIAP-1, 
cIAP-2, XIAP, A20, COX-2, IEX-IL, c-Myc, Bcl-2, Bcl-XL, TRAF-1, and TRAF-2 etc. 
 
NF-κB family comprises five members, which are RelA, RelB, c-Rel, p50 and p52 (21). 
These members form homodimers or heterodimers to bind to DNA. This binding is between 
the Rel homology domain (RHD) in the NF-κB and the κB sites in DNA. The latter is located 
in the promoters and enhancer regions of genes, which in turn regulates gene expression.  
RelA, RelB, c-Rel contain transcriptional activation domains (TADs) in their C-terminus and 
can activate target gene expression directly due to the TADs. p50 and p52 are derived from 
their large precursors, p105 and p100, respectively. p50 and p52 do not contain TADs; thus, 
they have to bind to a TAD-containing protein, such as RelA, c-Rel, or RelB, to execute their 
functions. The classic NF-κB dimer contains RelA and p50, while many other Rel-containing 
dimers also exist. In inactivated state, NF-κB is inhibited by inhibitory IκB proteins present in 
cytoplasm. Currently, seven IκB family members, IκBa, IκB, Bcl-3, IκBe, IκBg, and 
precursor proteins p100 and p105, have been identified. They all have the characteristic 
ankyrin repeats.  
 
As shown in Figure 1-2 (22), in an inactivated state, NF-κB, bound with the inhibitory protein 
IκB, is located in cytosol. A variety of extracellular signals can activate the enzyme IκB 
kinase (IKK), which in turn phosphorylates the IκB. This causes ubiquitination of IκB and its 
dissociation from NF-κB, and degradation by proteosome. The activated NF-κB is then 
translocated into the nucleus where it binds to specific DNA sites in target genes. This 
DNA/NF-κB complex recruits many other proteins such as co-activators and RNA 
polymerase to activate transcription of downstream DNA, resulting in a change of cell 




Figure 1-2. NF-κB mechanism of action (reproduced from reference (22)) 
 
1.2.2 NF-κB and two signaling complexes 
Signaling by tumour necrosis factor receptor (TNF-R1) can stimulate a plethora of seemingly 
opposing biological processes, ranging from inflammatory cytokine production, cell survival, 
cell proliferation, and cell death (25). TNF mediates most of its effects through activating a 
set of transcription factors that are collectively referred to as NF-κB (26). Binding of TNF-α 
to TNFR1 results in sequential formation of two signaling complexes (Figure 1-3). The 
rapidly forming complex-I is constituted on the receptor’s cytoplasmic tail and consists of 
TRADD, Sam68, RIPK1 (also named RIP1), TRAF2, TRAF5, and cIAP-1/2 (27). The 
TRADD is an adaptor. The RIPK1 is a protein kinase. Of note, TRAF5 can also be part of this 
complex; however, its clear function in complex-I is not known. The function of the signal 
transducer TRAF2 in this complex is to recruit the E3 ligases cIAP-1 and cIAP-2, which 
subsequently ubiquitylate several components of this complex, required for to recruiting 
LUBAC (the E3 ligase linear ubiquitin chain assembly complex), which in turn strengthens 
this complex by promoting further ubiquitylation. This above process not only stabilizes 
complex-I, but also activates TAK1 and IKK, which in turn phosphorylates IκB leading to its 
degradation and the release of NF-κB to regulate expression of its target genes important to 
cell survival. Thus, this complex signals cell survival through activation NF-κB. 
 
On the other hand, TNF can also induce cell death. Micheau and Tschopp (27) were the first 
to identify the cytoplasmic death-facilitating complex that is derived from the complex-I after 
TNF stimulation. It is usually called complex-II. After the dissociation of complex-I from the 
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receptor, TRAF2 and TRADD together with RIP1 associate with an adaptor protein FADD 
and pro-caspase-8 to form complex-II. Unlike the rapid formation of complex-I, complex-II is 
formed 2 hours later after ligation of TNF to TNF-R1. Complex-II signals apoptosis through 
activation of caspase 8. 
 
Remarkably, the apoptotic function of complex-II is manifested only under some special 
conditions where expression of NF-κB target genes is blocked, such as upon genetic deletion 
of NF-κB, expression of the IκB-super repressor (IκBSR), or in the presence of 
cycloheximide (27, 28). Thus, in normal condition, if TNF successfully stimulates 
NF-κB-regulated expression of target genes, formation of complex-II cannot lead to apoptosis. 
This is because NF-κB activation results in up-regulation of anti-apoptotic proteins, such as 
cFLIP, cIAP-1, cIAP-2, XIAP, which in turn suppresses cell death induced by complex-II (27, 
28). Thus, in order to induce TNF-α-activated apoptosis to cell lines, cycloheximide (CHX) is 
usually included. Cycloheximide is a protein synthesis inhibitor that can shut down synthesis 
of anti-apoptotic proteins, such as cFLIP, cIAP-1, cIAP-2, XIAP, induced by NF-κB. 
 
cFLIP, which suppresses caspase-8 in complex-II, contains 11 known isoforms. The two 
predominant isoforms are the long (cFLIPL) and the short (cFLIPS) (29). Unlike caspase-8, 
cFLIPL lacks a catalytic cysteine necessary for enzymatic activity, so despite its resemblance 
to caspase-8 in domain architecture; cFLIPL is just an inactive pseudo-caspase. cFLIPL and 
caspase-8 can form heterodimer. Through dimerisation-induced conformational changes of 
this heterodimer, cFLIPL mediates activation of caspase-8. Hetero-dimerization rotates the 
catalytic pocket of caspase-8 into position for catalysis, allowing cFLIPL-caspase-8 
heterodimers to be functionally active (30, 31). However, the weak catalytic activity formed 
by such process is not enough to trigger cell death, because cFLIPL prevents cleavage of the 
prodomain of caspase-8, and the active caspase-8 cannot be released from FADD. Moreover, 
heterodimers formed by cFLIPL and caspase 8 show less proteolytic activity than caspase-8 
homodimers on apoptotic substrates such as Bid and caspase-3 (31, 32). Unlike cFLIPL, 
cFLIPS only encodes the prodomain, which contains the death effector domain (DED) 
necessary for FADD binding. Unlike cFLIPL, which promotes localized activation of 









IAP, which serves as endogenous inhibitors of apoptosis, is a family of structurally and 
functionally related proteins. The eight human members include Apollon, ILP2, Livin, 
Survivin, NAIP, cIAP-1, cIAP-2, and XIAP (Figure 1-4) (36). The defining feature of an IAP 
family protein is the BIR repeat, a zinc-binding fold of about 70 amino-acids residues that 
mediates protein and protein interactions, and is essential for the anti-apoptotic potential of 
most IAPs (37-39). IAPs carry one to three copies of this domain. BIR domains can be 
divided into type I and type II domains according to the presence of a deep peptide-binding 
groove. Type I BIR domains only have a shallow pocket instead of a peptide-binding groove, 
whereas type II BIRs carry a distinctive peptide-binding groove which enable them to bind to 
N-terminal tetrapeptides known as IAP-binding motifs (IBMs) (40-42). Apoptosis regulatory 
IAPs such as XIAP, cIAP-1, cIAP-2, DIAP1, and DIAP2 (DIAP1 and DIAP2 are homologs in 
Drosophila) possess two type II BIR domains. All of these IAPs, except DIAP1, also carry 
one type I BIR domain (40). It is important to note that type I and II BIR domains possess 
different binding features. Type II domains interact with caspases or IAP antagonists. Type I 
 8 
BIR domains interact with other complete different set of proteins, such as TRAF1, TRAF2, 
and TAB1 (43, 44, 45). 
 
These IAPs also harbor some other domains such as the carboxy terminal RING finger 
domain which enables them with ubiquitin ligase (E3) activity (46). Besides, they comprise a 
ubiquitin associated (UBA) domain through which they interact with ubiquitinated proteins 
(47, 48). Furthermore, cIAP-1 and cIAP-2 contain a caspase recruitment domain (CARD), 
whose function is currently not clear. 
 
1.3.2 Function 
Apart from the primary function of IAPs as regulating caspases, IAPs also influence many 
other cellular processes. For example, these proteins can affect ubiquitin-dependent signaling 
events that regulate activation of NF-κB transcription factors. Besides, IAPs can regulate 
signaling events which are included in activation of cell metastasis (49, 50). Further, they 
modulate mitosis and proliferation. Many of these cellular processes are related to disease 
initiation directly or indirectly (51, 52). 
 
Furthermore, IAPs have important roles in tumour maintenance and resistance to 
chemotherapy treatments, although IAP expression on its own is clearly not the only 
determinant that increases apoptotic threshold and enables tumour growth (51-54). Cancer 
cells can propagate under unfavourable circumstances such as chromosomal aberrations, 
oncogene deregulation, hypoxia, DNA damage, and nutrient limitation. These adverse 
conditions while normally trigger caspase activation leading to apoptosis may fail to do so in 
cancer cells because of disordered expression and activity of IAPs.  
 
 
Figure 1-4. IAP family proteins (reproduced from reference (36)) 
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1.4 XIAP 
1.4.1 Discovery and function 
The first identified homolog of IAP family in humans is NAIP (55). NAIP has three BIR 
domains at N-terminus but no RING finger motif. It is mainly expressed in neurons where its 
role is to protect cells against apoptosis (56) and it plays a crucial role for survival of neurons 
in pathological condition (57, 58). Later, a RING finger- and three BIR domains-containing 
IAP family member was found, which was named as X-linked inhibitor of apoptosis protein, 
XIAP. The transcript size of XIAP is 9.0 kb. It has a 1.8 kb long open reading frame (55). The 
mRNA of XIAP has been found in all of human adult and fetal tissues except peripheral blood 
leukocytes (55). Other members of the IAP family proteins were identified in succession 
based on their homology to XIAP sequence. 
 
In vitro kinetic studies showed that XIAP had Ki values of 0.2 to 0.8 nM when compared with 
a 1-20 nM range for the other members of the IAP family proteins for inhibition of apoptosis 
(59). XIAP is known to be the most potent caspase inhibitor in the IAP family. XIAP inhibits 
both the initiator caspase 9 and the effector caspases 3 and caspases 7. Overexpression of 
XIAP efficiently inhibits caspase activation and apoptosis stimulated by the intrinsic 
apoptosis pathways and extrinsic apoptosis pathways (60-65). Conversely, cells that lack 
XIAP are sensitized to apoptosis (66-69).  
 
1.4.2 BIR domain of XIAP and its function as direct 
caspase inhibitor 
Among all of the members of IAPs, mammalian XIAP is the only one which can directly bind 
and inhibit caspase 3, caspase 7, and caspase 9, functioning as a direct caspase inhibitor (70). 
The potent ability of XIAP in inhibiting caspases owes to its BIR domains, which have 
distinct functions. Thus, XIAP inhibit initiator and effector caspases using different kinds of 
ways. 
 
The second BIR domain (BIR2) binds and inhibits the active site pocket of caspase 3 and 
caspase 7 by completely filling the active site to prevent entry of substrates (39, 71-75). It has 
been found that Gly144, Val146, Val147, and Asp148 of XIAP form either hydrogen bonds 
or Van der Waals interactions with caspase 7 substrate-binding sites S1, S2, S3, and S4, 
respectively (74). Of these interactions, the one between Asp148 and S4 is the most important 
for docking interaction (72). The structural arrangement between XIAP and caspase 3 is 
similar to that between XIAP and caspase 7 (75). Since caspase 3 and caspase 7 have almost 
the same backbone structures and share 54% sequence identity (74), binding of XIAP to 
caspase 3 is mediated by the same four pairs of residues as caspase 7 in a similar way (75). 
The four caspase-interacting residues, Gly144, Val146, Val147, and Asp148, are conserved 
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among XIAP and two other IAP family proteins, cIAP-2 and cIAP-1 (72). All of these three 
IAPs have a function in inhibiting the effector caspases 3 and 7 (76). 
 
There are two binding interactions between XIAP and caspase 3 and 7. Residues in the linker 
region between the BIR1 and BIR2 domain of XIAP bind to the active site pocket of caspase 
3 and caspase 7, occluding the substrate entry and resulting in the inhibition of the catalytic 
activity of these two effector caspases (39, 71-75). Besides, BIR2 domain of XIAP makes 
additional contact with an IBM motif present at the neo-amino-terminus of the activated 
caspase 3 and caspase 7 (75, 77). In non-active caspases, the IBM motif is hidden. It is only 
exposed in the active caspase 3 and 7 after a cleavage-mediated activation process. These two 
binding interactions strengthen the interaction with one another, which is essential for XIAP 
to dock effectively onto effector caspases for inhibition.  
 
It was shown recently that the isolated BIR3 domain is enough to inhibit caspase-9 potently 
(39). However, the mechanism by which XIAP inhibits the initiator caspase 9 is very different 
from its inhibition of the effector caspases 3 and 7. XIAP binds only to processed caspase 9, 
not to the inactive procaspase 9 (42). After recruitment of procaspase 9 to oligomerized 
Apaf-1 within apoptosome, small subunits, named p12, and a large subunit of caspase 9 can 
be released at Asp315 of procaspase 9 in an autocatalytic procedure. In normal condition, 
these two subunits join together to form dimer. In order to carry out its apoptotic function, 
caspase 9 requires a dimerization induced conformational change to generate a productive 
catalytic pocket. However, the XIAP BIR3 domain can bind directly with the new free amino 
terminus of p12, which is important for the dimerization (42, 78). This binding of XIAP to 
caspase 9 prevents the joining of large and small caspase subunits, and interferes with caspase 
9 dimerization. This kind of interference inactivates caspase 9 and blocks the caspase cascade. 
 
The function of the BIR1 domain of XIAP is still unknown. No data indicates that BIR1 of 
XIAP can inhibit caspases. Indeed, a truncated XIAP with only BIR1 domain, loses its 
interaction ability with caspase 3 or caspase 7, and cannot inhibit apoptosis (64). 
 
1.4.3 RING domain of XIAP and its function as E3 in 
ubiquitination 
Apart from BIRs, XIAP harbors a C3HC4 RING finger motif, which is a zinc-binding and 
carboxy terminal domain. The function of the motif was unknown when first discovered, but 
is now widely accepted as critically important to the ubiquitin ligase activity of 
RING-containing E3 ligases (79), by serving as the dimerization interface and docking site for 
ubiquitin conjugating enzymes (E2s). The change of a single zinc-chelating residue in this 
region can eliminate E3 activity (46). This RING finger enables XIAP to catalyze 
ubiquitination of self, XIAP interacting proteins involved in apoptosis, and other targets 
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whose physiologic roles likely extend beyond cell death (80). Furthermore, XIAP harbors a 
UBV domain, which allows XIAP to bind polyubiquitin (81). XIAP is capable of 
auto-ubiquitination in a manner dependent on the E3 activity, which counts on the RING 
domain itself. The general assumption has been that the auto-ubiquitination of XIAP is a K48 
ubiquitin conjugation process, which leads to proteasomal degradation (82). 
 
Two types of proteins can trigger or promote the ubiquitination of XIAP: 
(1) IBM-bearing antagonists of XIAP 
XIAP has two types of antagonists. One is of IBM-bearing antagonists, such as mitochondrial 
interaction proteins Smac/DIABLO, Omi/HtrA2, CLPX, LRPPR, GdH, Nsp4, or ER 
associated protein GstPT/eRF3, which have been described to bind and antagonize XIAP via 
their IAP-binding motifs (IBMs) potentially (83). The other type is of the antagonists that do 
not have IBMs, such as AIF and ARTS, which are thought to bind IAPs through distinct 
mechanisms independent of IBMs (84, 85). Only the IBM-bearing antagonists can trigger the 
degradation of XIAP in auto-ubiquitination degradation manner under some circumstances 
(86-89). The essential reason is that the binding of these IBM-containing XIAP-interacting 
proteins can induce a structural change to XIAP, which favours auto-ubiquitination. 
(2) Other RING-bearing IAPs 
Some other RING-bearing IAPs, such as cIAP-1, can cause the ubiquitination of XIAP. RING 
motif of cIAP-1 binds directly to the RING motif of XIAP. Via the E3 ligase activity of the 
RING from cIAP-1, XIAP is ubiquitinated and degraded by proteasome (90, 91). 
 
Apart from XIAP itself, the RING finger also modulates the level of other substrates in a 
similar manner. Some of them are involved in apoptosis, while some are related to other 
signaling pathways apart from death. These substrates are as follows: 
(1) Caspases 
Through the Ub ligase E3 activity of RING motif, XIAP is capable of caspase 3, 7, and 9 
ubiquitination in vitro and caspase 3 ubiquitination in vivo (73, 92). This type of 
ubiquitination has been linked to degradation and non-degradation inactivation of caspases 
(73, 81, 92). 
(2) AIF, Smac 
AIF, a positive intrinsic regulator of apoptosis, can cause DNA fragmentation and chromatin 
condensation, initiating a caspase-independent pathway of apoptosis. It also acts as an NADH 
oxidase. SMAC is a mitochondrial protein, which promotes cytochrome c-dependent 
apoptosis activation by eliminating XIAP . These two XIAP associated proteins, Smac and 
AIF, have been demonstrated to be the targets for ubiquitination through interaction with 
XIAP, which requires the RING finger (84, . 
(3) Survivin 
Another IAP family member, Survivin, has also been reported to be down-regulated by XIAP 
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via its RING motif (95). This process requires the synergism of another protein, XAF1. 
Survivin is also a member of the IAP family, which antagonizes the anti-caspase activity of 
XIAP and may be important in mediating apoptosis resistance in cancer cells. 
(4) TAK1 
TAK1 belongs to the serine/threonine protein kinase family. This kinase controls a variety of 
cell functions including transcription regulation and apoptosis and mediates signaling 
transduction induced by TGF β and BMP. This protein forms a kinase complex, which is 
required for activation of NF-κB in response to IL-1. The components of this complex also 
include TRAF6, MAP3K7P1/TAB1, and MAP3K7P2/TAB2. Furthermore, TAK1 plays an 
important role in cell response to environmental stresses by activating MAP2K4/MKK4 and 
MAPK8/JNK. XIAP can activate the NF-κB activity (96-98). The target of XIAP in this 
process is the serine threonine kinase, TAK1 (99, . This mechanism also requires an 
association with TAB, which is mediated by the BIR1 domain of XIAP (101, 102). XIAP can 
shut down the JNK activity also by promoting the ubiquitin-mediated degradation of TAK1 
via the RING finger. Once JNK is inhibited, the JNK-induced cell death is prevented . 
(5) MEKK2 
XIAP also directs the ubiquitination of the NF-κB-activating kinase MEKK2, which activates 
IκB kinases by phosphorylation directly. The non-K48 conjugated ubiquitin chains of 
MEKK2 are catalyzed by XIAP. Non-K48 ubiquitination has diverse non-degradative 
functions, which include altering protein structure, localization, interaction, or activity (103). 
(6) COMMD1 
XIAP is also a negative regulator of COMMD1, by promoting degradation of COMMD1 via 
the E3 ubiquitin ligase activity. COMMD1 is a NF-κB suppressor. COMMD1 binds to 
multimeric ubiquitin ligases containing Elongins B/C, Cul2, and SOCS1 (ECSSOCS1) to 
form a complex. In this complex, COMMD1 facilitates the binding of NF-κB to the ligase, 
thereby promoting ubiquitination and degradation of NF-κB (104). Apart from the function as 
a NF-κB suppressor, COMMD1 is also involved in a variety of other cellular functions, 
including hypoxia (105) and copper homeostasis (106). Whether XIAP also involved in the 
latter two activations needs further evidence to support (107, 108). 
 
1.4.4  XIAP associates with apoptosome 
Subsequent to the release of cytochrome c from the mitochondria to cytosol during apoptosis, 
the adaptor molecule Apaf-1 is oligomerized and procaspase-9 is recruited into apoptosome, a 
holoenzyme multi-protein ‘death’ complex. Caspase 9 is activated by the oligomerization of 
procaspase 9 in this complex. At the same time, caspase 3 is recruited and activated by either 
active caspase 9 or the procaspase 9. After that, the active caspase 3 is released from 
apoptosome to execute its function. Evidence shows that XIAP is associated with apoptosome 
where it interacts with either caspase 9 or caspase 3. It can prevent not only the release of 
caspase 3 from apoptosome but also the activation of caspase 3 by caspase 9 (109). 
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1.4.5 Antagonists of XIAP 
Smac/DIABLO is the best understood antagonists of XIAP, which promotes apoptosis. In 
normal condition, Smac/DIABLO is a catalytically inactive precursor protein located in 
mitochondria. Under activation of the mitochondrial apoptotic pathway, the 55 amino-acids 
amino-terminal targeting sequence of Smac/DIABLO is removed, resulting in exposure of the 
IBM domain for the binding to IAPs. Subsequent cytosolic release of the N-terminally 
cleaved Smac/DIABLO can promote apoptosis by binding to XIAP and inhibit its 
anti-apoptotic activity. Besides, Smac/DIABLO can likewise interact with other members of 
the IAP family proteins including cIAP-1, cIAP-2, and Survivin (110, 111). 
 
Another important inhibitor of XIAP is the XIAP-interacting protein (XAF1). In contrast to 
Smac/DIABLO which requires pre-processing for activation, this seven zinc 
fingers-containing protein can readily interact and inhibit XIAP directly (112). Of note, XIAP 
levels are relatively high in most cancers while the XAF1 levels are very low or even 
undetectable in various cancer cell lines (112). This phenomenon indicates that XAF1 may 
play an important role as a tumour suppressor (113). 
 
1.4.6 Clinical significance of XIAP 
Deregulation of XIAP can result in cancer, neurodegenerative disorders, and autoimmunity 
related disease (55, 65). XIAP is found overexpressed in cancer cells. XIAP mRNA, assayed 
by reverse transcription polymerase chain reaction, is a useful tumor marker for 
discriminating cancer tissue from normal tissue. It can be applied to lung cancer (114), 
prostatic epithelium cancer (115), and colorectal cancer (116) etc. Furthermore, combination 
of XIAP with other tumor makers, such as Survivin and CEA (carcinoembryonic antigen) can 
increase diagnostic performance (117). In addition to its function in cancer, deregulation of 
XIAP can result in abnormal autoimmunity related disease (65), such as the inflammatory 
bowel disease (118). Furthermore, XIAP is involved in neurodegenerative disorders (65). 
Defects in XIAP gene can also result in an extremely rare condition called X-linked 
lymphoproliferative disease (118).  
 
1.5 Ubiquitin and ubiquitination  
1.5.1 Overview of ubiquitin 
Ubiquitin, a small protein, has been found in almost all of tissues of eukaryotic organisms 
universally. It is named because of its ubiquitous expression. It is highly conserved among 
eukaryotic species: human and yeast ubiquitin has 96% sequence similarity. This small 
protein consists of 76 amino acids and has a molecular mass of about 8.5 kDa. The human 
ubiquitin sequence in one letter code is MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKE 
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GIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG. Its C-terminal tail and 7 
lysine residues are important for its structure and function. These 7 lysine residues are K6, 
K11, K27, K29, K33, K48, and K63.  
 
Ubiquitin can conjugate together to form isopeptide-linked polymers known as polyubiquitin 
chains. Most of the ubiquitin chains are built by formation of an isopeptide bond between 
Gly76 of one ubiquitin to the ε-NH2 group of one of the seven potential lysines (K6, K11, 
K27, K29, K33, K48, and K63) of the preceding ubiquitin. Specific E2 enzymes and E2/E3 
combinations result in the formation of linkage-specific ubiquitin chains. Mono-ubiquitin or 
different kinds of polyubiquitin chains have different conformations. They all can be attached 
to a large range of target proteins while mono-ubiquitin or different types of polyubiquitin 
chains play different roles on their targets. 
 
Residue K48 is a major site of chain initiation. K48-linked ubiquitin chain is constituted 
through isopeptide bond formation between the carboxy-terminal Gly76 of one ubiquitin and 
K48 residue of another ubiquitin. K48-linked ubiquitin chains can be attached to proteins and 
label them for degradation by proteasome. These chains display a rather twist conformation. 
 
The other principle and relatively abundant polyubiquitin chains have K63-linkages, which do 
not seem to play a role in protein turnover. Instead, K63-linked ubiquitin chains perform a 
more diverse set of functions, such as altering protein structure, localization (protein docking), 
interaction, or activity. The K63-linked polyubiquitin chains labeled proteins are related to 
receptor endocytosis and sorting, DNA damage repair, translation and stress response, etc. 
These chains, linked via the Gly76 of one ubiquitin and K63 of another ubiquitin, display an 
open conformation. 
 
Importantly, different from all of the chains linked by lysines, the head-to-tail linear ubiquitin 
chains are those linked via the C- and N-terminus of ubiquitins without involving any lysine 
residue of the ubiquitin. Linear ubiquitin chains can also alter protein localization (protein 
docking). They display an equivalent conformation to K63-linked chains. 
 
Protein mono-ubiquitination has been shown to play key functional roles that are apparently 
independent of degradation. It plays an important role as a signal in protein trafficking and 
extra-cellular receptor internalization (119). The mono-ubiquitin labeled proteins are related 
to enzymatic activity, endocytosis, DNA-repair, and transcription etc. (120). 
 
1.5.2 Ubiquitination process  
Ubiquitination is a process of marking a protein with ubiquitin, also named ubiquitylation or 
ubiquitination. The amide bond is formed between the epsilon amine of the lysine in the 
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modified protein and the carboxylic acid of the terminal glycine, located in the di-glycine 
motif, in the activated ubiquitin. As shown in Figure 1-5 (121), this enzymatic, protein 
post-translational modification process consists of a three main steps. The first step is the 
activation of ubiquitin in a two-step reaction by an E1 (ubiquitin-activating enzyme) requiring 
ATP as an energy source. Initially, an ubiquitin-adenylate intermediate is produced. Next, 
ubiquitin is transferred to E1 active site cysteine residue, releasing AMP at the same time. 
After that, a thioester linkage between the E1 cysteine sulfhydryl group and the C-terminal 
carboxyl group of ubiquitin is created. The second step of this cascade is transferring of 
ubiquitin from the cysteine of E1 to the active site cysteine of an E2 (ubiquitin-conjugating 
enzyme). This process is a trans (thio) esterification reaction. The third step is conjugating the 
C-terminal glycine of ubiquitin from the cysteine of E2 to a lysine of the target protein via an 
isopeptide with the help of E3 (ubiquitin-protein ligase), which is capable of interaction with 
both E2 and substrate. The substrate recognition responsibility owes to E3. That is why there 
are hundreds of E3s in the cell. In the ubiquitination cascade, the number constitution of E1, 
E2, and E3 is like a pyramid. A few E1V can bind with dozens of E2s, which can work with 
hundreds of E3s in a hierarchical way. Besides, other ubiquitin-like proteins (ULPs) are also 
modified via the E1-E2-E3 cascade analogously. 
 
Figure 1-5. Ubiquitination cascade (reproduced from reference (121)) 
 
1.5.3 Ubiquitin-activating enzymes, E1s 
Using ATP as energy source, the adenylation active site of E1 catalyzes an adenylylation at 
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the C-terminal of ubiquitin. This intermediate is usually called ubiquitin adenylation 
intermediate (122-124). After that, this intermediate is attacked by the catalytic cysteine of E1, 
producing a covalent thioester linkage between the cysteine sulfhydryl of E1 and the 
C-terminus carboxyl of ubiquitin, with the release of AMP at the same time (122, 123, 125, 
126). Thus, E1 binds two ubiquitin molecules at the same time at different active sites 
asymmetrically. One ubiquitin is linked to the cysteine of E1 via its C-terminal carboxy, 
forming a covalent thioester bond. The other ubiquitin is bound to the adenylation active site 
of E1 via its C-terminus non-covalently. Each step of the E1 reaction is reversible. 
Progression of the cascade is driven by releasing of the small molecule products PPi and AMP 
at different steps, respectively (122-124, 127, 128). 
 
For more than twenty years, it was accepted that there is only one ubiquitin activating enzyme, 
which can work with all of the E2s in ubiquitin system. This E1 is called UBA1. This 
118-kDa enzyme contains an adenylation domain. However, this central dogma has been 
challenged recently. A second E1 enzyme for ubiquitin was identified, which was called 
UBA6 or Ube1L2 (129, 130). UBA6 is charged by ubiquitin in vitro and in cells. Having the 
same molecular weight as UBA1, UBA6 shares around 40% identity with UBA1. UBA6 also 
contains an adenylation domain, which is responsible for ubiquitin recognition and 
acyl-adenylation. Different from UBA1, which charges most of the E2s, UBA6 is uniquely 
responsible for transferring ubiquitin to its selective E2, which is named USE1 (Uba6-specific 
E2) (129). UBA6 and USE1 are expressed broadly. They have been found in organisms from 
humans to zebra fishes, and even in sea urchins, but not in flies, worms, or yeasts. This 
expression pattern indicates a selective role of UBA6 and USE1 in a specific phylogenetic 
branch of metazoa that leads to humans. 
 
Apart from the above-mentioned two E1s for ubiquitin, other E1s have been found for 
ubiquitin-like proteins, which are also modified via the E1-E2-E3 cascade similarity. These 
E1s together with their selective E2s and ubiquitin-like proteins are: UBE1L, which shares 
46% identity with UBA1, is specific for ISG 15, working together with the E2, UbcH8 (131). 
ISG15 is a ubiquitin-like protein that becomes conjugated to many cellular proteins upon 
activation by interferon-α and -β (132). Both APP-BP-1 and UBA3 can activate NEDD-8 
using UBC12 as their unique E2 (133). The ubiquitin-like proteins SUMO 1, 2, 3 can be 
activated by either AOS1 or UBA2 with the help of their unique E2 UBC9 (134, 135). The 50 
kDa E1 UBA4 is specific for URM-1, while their E2 is unknown (136). E1 UFM-1 and E2 
Ufc1 are unique for the ubiquitin-like protein UBA5 (137). E1 for ATG12 and ATG8 is ATG7. 
ATG means autophagy-related. ATG7 shows homology to the ATP-binding and catalytic sites 
of UBA1. ATG12 and ATG8 are ubiquitin-like proteins. ATG12, ATG8, and ATG7 are 
indispensable for formation of the autophagosome (138). Their E2s are ATG10 or ATG3 (139). 
Of note, the UBA6 which is the E1 for ubiquitin, can also activate the ubiquitin-like protein 
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FAT10 (129, 130, 140).  
 
1.5.4 Ubiquitin-conjugating enzymes, E2s 
With the active cysteine of E2, ubiquitin is transferred from the cysteine of E1 to a cognate E2. 
This a trans (thio) esterification reaction which creates a high-energetic conjugation between 
the C-terminus of ubiquitin and the cysteine of E2 (123, 127, 128). The characteristic of E2s is 
their ubiquitin-conjugating catalytic (UBC) fold. This 150-200 amino acids, 14-16 kDa 
domain is highly conserved among different family members , 142). This domain provides a 
platform for the interactions between ubiquitin (or ubiquitin-like proteins), E1s and E3s (142). 
The key residue of this domain is the embedded catalytic cysteine, which conjugates the 
ubiquitin or ubiquitin-like protein via thioester bond first. Then it interacts with E3 prior to 
the subsequent substrate conjugation. 
 
Each ubiquitin-conjugating catalytic fold can be divided into three shells of amino acids. The 
cysteine and conserved residues surrounding it are embedded in the first shell. The cysteine 
has direct catalytic activity while the residues surrounding it regulate the ubiquitin 
conjugation directly. These residues are solvent approachable and regulate the activated 
ubiquitin. The second shell contains the inner core structures and overlaps with the first shell 
partially. The actual surface residues constitute the third shell, which are important for the 
interactions of E2 with other proteins, like E1 and E3. 
 
Up till now, around a dozen ubiquitin-like proteins have been found, such as ISG15, SUMO-1, 
2, 3, NEDD-8, URM-1, UFM-1, FAT10, ATG12, ATG8, etc. Almost each of those has its own 
particular E2 specificity. Thus, the conjugation between ubiquitin and ubiquitin-like proteins 
with E2s is parallel . However, some comprehensive crosstalks between different pathways 
may happen. For example, crosstalks between ubiquitin and ISG15 conjugation pathways 
(143) and between ubiquitin and SUMO (small ubiquitin-like modifier) (144) have been 
identified. E2 enzymes have been found in all of eukaryotes, emphasizing the significance of 
ubiquitin systems in biology (145, 146). The family protein is expanded during evolution. The 
higher the eukaryotes are, the more E2s they possess (145). Thirty-five E2s have been 
identified in humans to date. Other eukaryotic genomes have sixteen to thirty-five E2 family 
members. 
 
Depending on the presence of additional extensions to the catalytic core, E2s have been 
grouped into four types. Class-I only harbors the catalytic domain. Class-II and III have 
additional N- and C-terminal extension, respectively; whereas Class-IV has both extensions , 
146). Because of these extensions, different E2 enzymes have marked differences in size. For 
example, class-I E2s, like UbcH5B (UBE2D2) and hHR6A (UBE2A) are small molecular. 
The size of other E2s is larger. For example, Ubc12 (UBE2M) and UbcH6 (UBE2E2) of 
 18 
class-II and class-III UBE2U, containing non-conserved extensions, can reach 200-400 amino 
acids in size. The functions of E2 are also different because of these extensions. These 
functional differences include modulation of the activity of E3, stabilization of interaction 
with E1 and subcellular localization. 
 
1.5.5 Ubiquitin-protein ligases, E3s 
E3s are a large, diverse group of proteins. They can be divided into three main types depend 
on different defining motifs. The first group is HECT, which can catalyze ubiquitin directly. 
The other two types are RING and U-box, which promote protein ubiquitination indirectly. 
RING and U-box work like an adaptor, which performs as a platform to bring together the E2 
and substrate ubiquitination of the latter. 
 
As mentioned above, proteasomal degradation of proteins is not always the primary function 
of ubiquitination. E3s together with their substrates are identified to have diverse and wide 
functions. For example, RING type E3 TRAF6 and its substrate NEMO are necessary in 
NF-κB processing and NF-κB activation (147). Interestingly, the levels of E3s themselves can 
also be regulated by proteasome-mediated degradation via self-regulation by 
auto-ubiquitination (148-151). 
 
1.5.5.1 HECT domain E3s 
After the identification of the first E3, E6-AP1, a total of 28 human HECT type E3s, which 
contain a similar 350 amino-acids catalytic cysteine domain have been characterized by 
database searches (152). Similar to the E2, a thioester bond is conjugated between the central 
cysteine residue within the HECT domain and the carboxy group of the C-terminal glycine 
ubiquitin. E2 accepts ubiquitin before transferring it to the substrate. Whereas the C-terminal 
HECT domain contains E3 activity of ubiquitin conjugation, the N-terminal domain, many of 
which are larger than 100 kDa, is responsible for substrate binding. The members of HECT 
E3s together with their targets have been demonstrated to have a role in disease processes, in 
particular in cancer. These cancer related E3s and their targets are shown in Table 1-1 (153). 
HECT E3s use multiple ways to form polyubiquitin chains. For example, the E6AP builds 
K48-linked chains. The UBE3C constitutes K48- and K29-linked chains to the targets , 155). 
Besides, the Rsp5 prefers to build up K63-linked chains (156). 
 

















































































































































1.5.5.2 RING finger E3s 
This RING type E3 contains many more members than other types of E3. To date, hundreds 
of proteins containing a RING finger domain have been identified in mammalian genomic 
databases (157, 158). Of note, although their structures suggesting an E3 function, not all of 
the proteins containing this finger motif have the activity in vivo. The function of RING is not 
direct. It acts as scaffolding partners, facilitating the interaction between an E2 and a substrate 
(157, 158). The RING finger domain is defined as Cys1-Xaa2-Cys2-Xaa9-39-Cys3-Xaa1-3- 
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His4-Xaa2-3-Cys/His5-Xaa2-Cys6-Xaa4-48-Cys7-Xaa2-Cys8 (where Xaa can be any 
amino-acid residue) (157). The two important factors of the domain are the cysteine/histidine 
and zinc atoms, which are important in promoting both of protein-protein and protein-DNA 
interactions. Depending on whether a cysteine or histidine residue is found at Cys/His5 within 
the motif, RING finger motifs are further subdivided. The RING-HC type RING contains a 
Cys5 while the RING-H2 type RING contains His5. Both of the Cys5 and His5 are important 
for E2 recognition. Two zinc atoms in the RING are complexed by the cysteine/histidine 
residues in a ‘cross-brace’ manner, which is structural important for correct folding and 
biological activity of the RING domain. See Figure 1-6 (159). 
 
RING E3s come in four molecular architectures: single chain, homo-dimeric, hetero-dimeric, 
and multi-component. In large RING-containing complex, the other components in the 
complex facilitate the functional specificity and potency of the RING type E3. The 
best-known complex of this kind is the anaphase-promoting complex. Since there are 
hundreds of pairs of RING E3s and their substrates, the functions of them are wide and 
diverse in cell. These functions are related to apoptosis and cancer, neurological disorders, as 
well as a host of other conditions. See Table 1-2 (159). 
 
Table 1-2. RING type E3s and their target(s) 
Disease  E3 Target(s) 
Breast/ovarian BRCA1, BARD1 H2A, H2B, H3, H4 
Colonic, gastric SCF Multi-complex β-catenin, NF-κB 
Renal cell carcinoma 
and others 
VCB Multi-complex HIF-1α, HIF-2α 





Lung cancer, prostate 
cancer 
XIAP 
XIAP, caspases 3 and 






ALS Dorfin Mutant SOD1 
Neurological 
disorders 











Figure 1-6. Structure of RING finger (reproduced from reference (159)) 
 
1.5.5.3 U-box E3s 
U-box, 74 amino-acids domain, shares similar structure with the RING finger domain (160, 
161). The difference is that the U-box does not contain the important Zn required for metal 
chelation. Thus, it utilizes a salt bridge instead of zinc chelation to maintain correct folding. 
Similar to the RING, some of the U-box E3s can work independently while some others have 
to associate with other multi-proteins to exert the E3 function. Famous well studied U-box E3 
is CHIP, which has multiple substrates. CHIP and its substrates are related to neurological 
disorders, such as Parkinson’s disease, ALS, and Alzheimer’s disease. 
 
1.5.6 Proteasomes 
1.5.6.1 Overview of proteasomes 
The major enzyme system catalyzing the degradation of intracellular proteins is the ubiquitin 
proteasomes system. This catalytic system carries out its function hierarchically. Firstly, 
unwanted protein is tagged by K48-linked polyubiquitin chains via the E1-E2-E3 cascade. 
Then this protein is degraded in the proteasomes with the ubiquitins released and recycled. 
The proteasomes consist of two components, the key 20S proteasome containing the active 
site to fulfill the degradation and the 19S regulatory particles, which is important to pre-treat 
folded substrates. Depending on the number of the attached regulatory 19S, the proteasomes 
appear in various forms. One 19S regulatory particles binding to one end of the 20S constitute 
the 26S proteasome, which is the most common type of proteasomes. The 20S attached by 
double 19S composes 30S proteasome. Besides, hybrid proteasomes are also been identified. 
The three-dimensional shape of the 20S proteasome looks like a cylinder. Proteins are 
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degraded down into small peptides of 3 to 25 amino acids by 20S. 
 
Although 20S proteasome is pivotal for protein degradation, it is extremely inefficient in 
degrading folded substrate. The polyubiquitin conjugated and folded substrates need to be 
pre-processed by the multi-subunit 19S regulatory particles. This regulatory 19S, attaching to 
one or two ends of 20S, contains multiple functions. It recognizes and captures its substrates. 
It initiates substrates unfolding and facilitates their translocation from 19S to the central 20S. 
Besides, this complex has deubiquitinating activity, which can remove polyubiquitin chains 
from substrates. After that, the ubiquitin is released and can be re-used by cell (162-165). 
 
1.5.6.2 19S regulator complex 
The 19S regulator, also named cap, is a multi-protein complex composed of two 
sub-complexes, base and lid. Eight different non-ATPase subunits, Rpn3, Rpn5-Rpn9, Rpn11, 
and Rpn12, constitute this upper sub-complex, lid. The base is constituted by eight subunits. 
Six of them, named Rpt1-Rpt6, harbor ATP-hydrolysing activity, while the other two, name 
Rpn1 and Rpn2, are non-ATPase. The Rpn1 and Rpn2 are the largest subunits of 19S. Base 
and lid are conjugated by Rpn10.  
 
The 19S pre-treats its substrates prior to the final destruction in the following way: 
(1) A subunit in the lid recognizes substrates. The 19S has the ability to bind ubiquitinated as 
well as several non-ubiquitinated substrates. 
(2) An unstructured initiation site of base anchors the substrates via polyubiquitin chains. 
After that, the substrates begin unfolding by the same site. 
(3) In non-activated state, entrance pore of 20S is closed partially. This is done by the 
N-terminus of the α subunits of 20S, which form a mesh to separate the 20S. Upon 
completing the unfolding of the substrate, docking of the 19S will displace this N-terminus to 
open the entrance pore. 
(4) With the help of 19S, the unfolded protein can be translocated from 19S into the chambers 
of 20S through the entrance pore formed by the α ring. 
(5) Rpn11 in lid contains deubiquitinating function, which removes the polyubiquitin chains 
from substrates (166). 
 
1.5.6.3 20S, 26S, and 30S proteasomes 
The 20S is the pivotal complex, which catalyzes substrates degradation. The 20S is a high 
molecular-mass complex. The shape is like a cylinder or barrel. The size is 11 nm ×15 nm. 
This complex is built up by four stacked rings. The internal two stacked rings each consists of 
seven β subunits. The two outer rings, composed of seven α subunits, are attached to the two 
ends of β rings, respectively. Thus, the overall architecture of 20S is α1-α7/β1-β7/β1-β7/α1-α7. 
Based on the function of 20S, it can be divided into several segments. The entrance and exit 
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pores are built up by α rings. Between the rings of α and β subunits, the pores enlarge into 
antechambers. The antechambers enlarge further into proteolytic chamber, which is built up 
by the inner walls of β rings.  
 
With the help of 19S, the entrance pore opens to allow the substrate entering. The unfolded 
protein accesses to the proteolytic chamber through the antechamber. The volume of this 
proteolytic chamber is around 84 nm
3
. It is the site for catalysis of peptide bond hydrolysis. 
The N-terminal threonine residues, located in the inner wall of β rings, contain the active site. 
The degraded products, small peptides of 3 to 25 amino acids, leave 20S through the other α 
ring pore. After that, the amino acids are released and can be re-used by cell. The complete 
function of proteasomes is based on the cooperation of 19S and 20S. The conjugation between 
them requires the binding of ATP to the 19S ATPase subunits (167). 
 
1.5.7 Deubiquitinating enzymes  
1.5.7.1 Overview of deubiquitinating enzymes 
These deubiquitinating enzymes (DUBs) play several roles related to ubiquitin pathway: 
(1) DUBs have the function to activate ubiquitin proproteins. This procedure is likely to be 
cotranslational. 
(2) In ubiquitination process, some ubiquitins may be captured by small cellular nucleophiles 
accidentally. DUBs have the function to remove these wrongly connected ubiquitins and 
release them for re-use. 
(3) The ubiquitination of target proteins can be controlled by DUBs negatively. DUBs release 
the ubiquitin from target substrate. 
(4) Not all of the polyubiquitin chains synthesized by cell are useful. These include the free 
polyubiquitin or unanchored polyubiquitin. Some of these are produced de novo by 
conjugating system, while some are released from target proteins. DUBs have the additional 
function to unpack free polyubiquitin chains to regenerate mono ubiquitin. 
(5) DUBs can also reverse the ubiquitin-like modification of target proteins.  
 
DUBs are members of proteases. Proteases form a superfamily, which contains 561 members 
in human genome (168). According to their catalytic mechanism, they are further grouped 
into five classes, which are aspartic, metallo, serine, threonine, and cysteine proteases. They 
can be divided further depending on phylogeny. However, only two types of proteases 
cysteine and metallo have DUBs. 
 
Most DUBs are cysteine proteases. Three residues, cysteine, aspartate, and histidine consist of 
the catalytic triad. In this triad, the aspartate residue polarizes the histidine. While the 
histidine in turn de-protonates the adjacent cysteine. The thiol group of the cysteine contains 
the active site. During catalysis, the carbonyl of the scissile peptide bond between target and 
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ubiquitin is attacked by the catalytic active site of cysteine. After this nucleophilic attack, two 
components are released. One is the target protein. The other is a covalent intermediate 
formed by DUB and ubiquitin. The intermediate, which contains an oxyanion, has to be 
stabilized in oxyanion hole, which is composed of the main chain of the catalytic cysteine, a 
glutamine, glutamate, or asparagine residue. Then the intermediate reacts with a water to 
generate free DUB and ubiquitin. 
 
In the metalloprotease, Zn
2+
 atom is stabilized by an aspartate and two histidine residues. The 
stabilized Zn
2+
 bond in turn polarizes water molecule to generate an intermediate formed by 
DUB and ubiquitin. Different from the cysteine proteases, the conjugation of the intermediate 
is non-covalent. By proton transfer from a water molecule, the intermediate is broken down, 
releasing free DUB and ubiquitin (169). 
 
Depending on ubiquitin protease domains, the cysteine protease DUBs can be divided into 
four subclasses. They are ubiquitin-specific protease (USP), ubiquitin C-terminal hydrolase 
(UCH), Otubain protease (OTU), and Machado-Joseph disease protease (MJD). Since the 
metallo-DUBs have catalytic domains called JAMM (Jab1/Mov34/Mpr1 Pad1 N-terminal+), 
these metalloproteases are also named as JAMM. Human genome encodes around 95 DUBs. 
They are 58 USP, 4 UCH, 5 MJD, 14 OTU, and 14 JAMM domain-containing genes (170). 
 
The activity of cysteine type DUBs can be inhibited by N-Ethylmaleimide (NEM). NEM is an 
organic compound that is derived from maleic acid. It contains the imide functional group, but 
more importantly it is an alkene that is commonly used to inhibit and modify all of cysteine 
residues in proteins and peptides, with alkylation occurring at the active site thiol group of 
cysteine residues (171, 172). The resulting thioether features a strong C-S bond and the 
reaction is virtually irreversible. Please see Figure 1-7 (173).  
 
 
Figure 1-7. Mechanism of irreversible inhibition of a cysteine peptidase with NEM 
(reproduced from reference (173)) 
 
1.5.7.2 Ubiquitin C-terminal hydrolases (UCHs) 
UCHs were the first discovered DUBs. Four proteins, which are highly homologous in their 
catalytic domains, form the human UCH subclass of DUBs.  
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Their functions have the following features: 
(1) When ubiquitins are captured by small cellular nucleophiles, such as glutathione, 
polyamines, inappropriately, UCHs act in the recycling of these wrongly conjugated ubiquitin. 
(2) UCHs may be involved in the processing of newly synthesized Ub, which is translated 
either as a polyubiquitin precursor or fused to a ribosomal protein (170). 
(3) Based on the biochemical and structural results, UCHs prefers to cleave relatively small 
protein substrates, which contain less than 20 to 30 amino acids, from ubiquitin (174). 
(4) UCHs cleave poly-Ub variants with varying efficiency. For example, the yeast DUB Ubp2 
prefers to cleave K63- over K48-linked Ub chains as a substrate (175). UCH-L5 cleaves 
various types of polyubiquitin chains except linear dimers.  
 
1.5.7.3 Ubiquitin-specific proteases (USPs) 
USPs consist of 58 members, which are the largest subclass of DUBs. The catalytic domain of 
USPs is composed of Cys and His boxes, which are two short and well-conserved motifs. 
However, this catalytic domain is not sufficient to carry out its DUB function. It must work 
together with large unrelated, regulatory sequences, which are interspersed between Cys and 
His boxes. With different size of regulator, the size of complete catalytic domains of USPs 
varies from around 300 to 800 amino acids. 
 
Not all members of USPs have complete catalytic triad. Take the USP30 and USP16 for 
example; they lack the aspartate, which are important to polarize the histidine. Nevertheless, 
they retain the catalytic function. This conflict indicates that some of USPs may use a 
different residue to stabilize the active site. Significantly, some members of USPs, such as 
USP16, USP30, USP39, USP45, or USP52, which lack the important Cys or His, indeed 
cannot cleave ubiquitin. So they are renamed as ubiquitin-specific protease variant (USPV), 
which are not real DUBs. The functions of these variants with respect to ubiquitin need to be 
further investigated (170). 
 
Different members of USPs prefer different types of polyubiquitin conjugated substrates. For 
example, USP8 and USP14 can cleave K48- but not K63-linked Ub polymers (90, . In vitro 
assay reveals that some members of USPs, such as IsoT, USP2, USP15, and CYLD can cleave 
linear ubiquitin chains (177). It should be noted that in vivo assay for the above activity is not 
yet available. In vivo, only proteins, RIP1 and NEMO, which are involved in TNF-α-induced 
NF-κB signaling pathway, have been found to be substrate of linear ubiquitin chains. In this 
signaling pathway, ubiquitination of NEMO by K63 and linear ubiquitin, ubiquitination of 
RIP1 by K63, K11 and linear ubiquitin (147), are essential for NF-κB activation. CYLD can 
remove ubiquitin chains from NEMO (178) and RIP1 (179), thereby inactivating NF-κB 
activation. However, whether CYLD can remove the linear ubiquitin chains from NEMO and 
RIP1 has not been studied, needing further investigation (179, 180). 
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1.5.7.4 Machado-Joseph disease protein domain proteases (MJDs) 
Ataxin-3 mutation is involved in a neurodegenerative poly-glutamine expansion disease 
called spinocerebellar ataxia type 3. Ataxin-3 and some Ataxin-3-like proteins constitute the 
MJDs subclass, which are characterized by a domain called Josephin. The similarity between 
this domain and other DUBs is quite low (181, 182). Ataxin-3 preferentially cleaves K63- 
over K48-linked polyubiquitin chains. It prefers to cleave longer over shorter chains (183). 
 
1.5.7.5 Ovarian tumor proteases (OTUs) 
The first named OUT members are Otubain-1 and Otubain-2, which are found to be able to 
cleave ubiquitin chains in vitro (184). After that, another OUT domain-containing protein, 
Cezanne was identified to harbor DUB activity in vitro and in a yeast two-hybrid assay (185). 
A20, a potent inhibitor of NF-κB signaling, is a well-known member of OUTs. In vitro, A20 
can cleave both K48- and K63-linked Ub polymers with similar efficiency. However it only 
works for K63-linked but not K48-linked polyubiquitinated RIP in vivo (186). For most of the 
OTUs, their physiological functions remain to be investigated further. Unlike other cysteine 
protease DUBs, the OUTs lack the complete catalytic triad and their active site is stabilized by 
another means, which is related to a hydrogen bonding network (187). 
 
1.5.7.6 JAMM motif proteases 
JAMM is a widely expressed subclass, which can be found in all three major kingdoms of life, 
bacteria, archaea, and eukarya. Although bacteria have JAMM, they lack both ubiquitin 
protease activity and ubiquitin-like system. This phenomenon points out two indications: 
(1) During evolution, JAMM domains have received some new protease functions. 
(2) Some of human JAMM proteases may have diverse set of functions apart from DUB 
function. 
Not all members containing JAMM harbor DUB function. The ones with at least one amino 
acid changed in the conserved Zn
2+
 ion-stabilizing residues are not a de novo DUBs (170). 
 
Some members of this type are K63 selective DUBs. For example: AMSH, a K63-selective 
DUB , participates in multivesicular body sorting. Poh1, which is a stoichiometric subunit of 
19S (PA700) proteasome regulatory complex, is also a K63 selective DUB (188). The specific 
disassembly of K63-linked chains is a property of BRCC36, which is one member of BRISC 
and BRCA1-A complex (188). Jab1 is anther JAMM type DUB. It is one member of CO9 
signalosome (CSN). The CSN also contains a K63-selective DUB activity, which is due to its 
association with BRCC36 (188). 
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1.6 Background of BRE  
1.6.1 DNA and RNA of BRE  
1.6.1.1 Transcript variant of human and mouse BRE  
BRE, brain and reproductive organ-expressed, also named TNFRSF1A modulator, BRCC4 or 
BRCC45. Its gene (NCBI gene ID 9577) is located at 2p23.2, from telomere to centromere. It 
starts from 28,113,557 to 28,561,767 bp, containing a total of 448,284 bases. It has two 
flanking genes, which are RBKS 2p23.3 and RPL23AP34 2p23.2. They are located in minus 
strand orientation and positive strand orientation, respectively. 
 
The gene of human BRE contains fifteen exons (1 to 12, X, Y, and Z). See Figure 1-8 (189). 
Exons X, Y, and Z are alternatively spiced. The exon X is located between exon 1 and 2 at the 
5’ end, while the exon Y and Z are located between exon 11 and 12 at the 3’ end. By 
alternative splicing predominantly at 5’ or 3’ end, a total of six transcript variants are 
produced. Three of them (αa, αb, αc) are produced by alternative splicing at the 3’ end and 
one splicing between the exon 1 and 2 at the 5’ end. Only these three transcripts are functional, 
which produce 3 protein isoforms with distinct C-terminus. The other three (βa, βb, βc) 
involve splicing in an additional exon between the exon 1 and 2 at the 5’ end. These three 
transcripts are expected to be nonfunctional. The main BRE protein is encoded by the major 
transcript αa (also named as variant 3 by NCBI). This protein is 383 amino-acids long, named 
‘protein isoform 2 (NP-954661.1)’ by NCBI. In the major transcript αa, the alternative exons 
X, Y, and Z are not present. The exon 1 is non-coding. Its translation starts from ATG in the 
exon 2 (190). In human cells, all of the predominant splice variants are found to be 
co-expressed at different ratios. The normal cells lines express lower level of BRE than the 
cancer cell lines (190).  
 
In the mouse, alternative splicing only occurs to the 5’ end, which results in putative protein 
isoforms with different N-terminus. Some of these transcripts are predicted to be functional. 
The major transcript is named as variant 5 by NCBI. The protein encoded by this major 
transcript is a ubiquitous 383 amino-acids protein. It shares 99% similarity with human BRE. 
The other minor transcript variants are not co-expressed with the main one in all tissues, and 
are expressed differentially in different tissues. The mouse BRE alternative transcripts are 




The transcription start site is located differently over the region between 35 to 112 bases 
upstream of the last base of exon 1. The most frequent transcription start site is located at 40 
bases upstream of the last base of exon 1. Initially, the mRNA of BRE was found to be highly 
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expressed in brain and reproductive organs. This is why it was named ‘BRE’. Now it has been 
determined that the mRNA of BRE is expressed ubiquitously. The highest mRNA of BRE is 
expressed in adrenal and heart (189, 192). 
 
1.6.1.3 Mutations 
Based on the data of 4 populations (Europe, China, Japan, and Yoruba), the number of SNP in 
BRE gene is 453. This number is consistent with the size of BRE gene (448284 bases), as the 
observed frequency of SNP is 1 per 1000 bp of contig sequences (193). However, none of the 
SNPs is located in the coding exons of BRE. One SNP is located in the 5' UTR while the rest 
are in the introns. Two recombination hotspots have been located in the introns of BRE. One 
is from position 28271535 to 28276573, while the other is from position 28338948 to 
28341210. 
 
BRE gene contains a large CNP (copy number polymorphism) with losses and gains at 
different segments, and some small CNP regions (three-copy losses and two-copy gains). The 
large CNP region, containing 163295 bases, is at the 5’ end. The most downstream small CNP 
region in the 3’ end is located near exon Z. (The data is obtained from International Hap Map 
Consortium, 2003 (189). Two mutations of BRE in cell lines have been found in lung 
carcinoma and clear cell renal cell carcinoma, respectively. 
 
 




The major isoform of BRE (isoform 2) contains 383 amino acids with a molecular weight of 
44 kDa. It is a highly conserved protein. No homolog has been found within the same species. 
The crystal structure of BRE is not available. The 333 residues at the N-terminus are 
considered as a unique domain pfam06113. Besides, it has two UEV domains. One is located 
from residues 30 to 147 at the N-terminus and the other from residues 275 to 363 at the 
C-terminus (194). UEV domain is an Ub interaction motif, which strongly resembles the 
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catalytic domain of E2. Although it has the ability to bind ubiquitin, it lacks catalytic activity 
because of the lack of a cysteine necessary for the formation of a thioester-ubiquitin 
intermediate (195). UEV domains of BRE are important for interactions with other members 
of the BRE-containing complex (196, 197), and for binding to polyubiquitin chain (194). 
 
All of examined mammalian cell lines express high level of BRE. These included HeLa, 
HepG2, HL60, Jurkat, KRC/Y, MCF7, NIH3T3, NS0, THP-1, and lymphoblastoid CB14022 
cells, etc. (189). Among different mouse tissues, the expression level of BRE is different. The 
order is: lungs = spleen = thymus > adrenal > testis = kidney > brain > heart = liver (198). 
 
1.6.3 BRE in two complexes 
BRE is expressed in cytosolic and nuclear compartments (199). In nucleus, BRE is one part of 
the BRCA1-A complex. This complex has the following functions: 
(1) It is an E3 ubiquitin ligase. For example, the C-terminus of p53 can be ubiquitinated by 
BRCA1-A complex (200).  
(2) It is also a deubiquitination enzyme. For example, it can specifically remove K63-linked 
polyubiquitin chains from K63-linked ubiquitinated H2A and H2AX. 
Through the functions as E3 and DUB, BRCA1-A complex is important in DNA repair and 
cell cycle regulation (194, 200).  
The components of BRCA1-A complex are BRCA1, BARD1, Abraxas/Abra1/CCDC98, 
RAP80, BRCC36, BRE, and MERIT40/NBA1 (194, 200-203). See Figure 1-9. The 
interactions of these components are as follows: 
(1) RAP80 contains a tandem ubiquitin-interacting motif domain (UIM) at its N-terminus, 
which is required for its binding with ubiquitin (204). 
(2) RAP80 interacts with the BRCT domain of BRCA1 (201). 
(3) MERIT40 interacts with BRE directly and robustly via the C-terminal UEV domain of 
BRE and C-terminal PxxR of MERIT40 (197).  
(4) BRCC36 interacts with the N-terminal UEV domain of BRE (196). 
(5) Abraxas and BRCC36 interact with each other through the coiled-coil domains on both 
proteins, positioning a MPN+MPN-domain pair in the complex (194, 205).  
(6) RAP80 associates with a large region of Abraxas. This region contains N-terminal 
three-fourths of Abraxas, including ABR domain and coiled-coil domain (205, 206). 
(7) BRCT domain of BRCA1 binds directly to C-terminal SPxF motif of Abraxas in a 
phosphorylation-dependent manner (205-207).  
(8) BRE interacts with Abraxas directly via the N-terminus (residues 1-200) of BRE and the 
N-terminal ABR region of Abraxas (197). 
 
The functions of each component are as follows:  
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(1) Rap80 contains UIM domain, Abraxas-interacting region (AIR) and Zn finger (194). It 
acts upstream of BRCA1. It recruits BRCA1 to MDC1-γH2AX-dependent K63-linked 
ubiquitin polymers at DSBs (201, 204). Furthermore, it is necessary for recruiting BRCC36 to 
its K63-linked polyubiquitinated substrates, such as histones H2A and H2AX at DSBs (201, 
205, 208, 209). 
(2) MERIT40 contains a VWA domain at the N-terminus (194). It is important for maintaining 
BRE and Abraxas abundance (194). It regulates BRCA1-A retention at DNA breaks primarily 
via a role in maintaining the stability of BRE (202, 203).  
(3) Abraxas possesses MPN-domain at its N-terminus, coiled-coil domain and SPxF domain 
at its C-terminus (194). It is essential for the integrity of BRCA1-A complex (194). The 
interaction between Abraxas and BRE and interaction between Abraxas and BRCC36 can 
influence the whole complex formation (202). Abraxas mediates the interactions of both 
Rap80 and BRCC36 with BRCA1 (205). 
(4) BRCC36 is a deubiquitinating enzyme (202). It specifically catalyzes K63-linked 
polyubiquitin chains (188). It contains MPN+ and coiled-coil domains (194). It is mainly 
associated with deubiquitination of H2A/H2AX K63-linked polyubiquitination during DNA 
repair (201, 210, 211). Through DUB function towards its histone substrates, it may work to 
release the BRCA1-A machinery from these foci once the necessary repairs have been made 
(188). Besides, BRCC36 also exerts K63 specific DUB function toward some other 
unspecified yet non-histone substrates (188, 201, 211).  
(5) BRE is essential in maintaining the integrity and the DNA-repair function of this complex 
(197, 200, 202).  
Taken together, each member of BRCA1-A complex is responsible for the integral functions 
of BRCA1-A complex (194). 
 
In cytoplasm, BRE is one part of the BRISC (BRCC36 isopeptidase) complex. The 
components of this complex are ABRO1/KIAA0157, BRCC36, MERIT40/NBA1, and BRE. 
See Figure 1-9. BRE is critical for maintaining the integrity and function of the BRISC (197). 
This complex specifically cleaves K63-linked polyubiquitin chains (188). The K63-Ub 
substrate of BRISC is unknown. Which protein in the BRISC can target the complex to its 
substrate is also unknown. (196). Unlike RAP80, ABRO1 does not contain the 
BRCA1-interacting motif. Thus, the BRISC complex does not interact with BRCA1 (197). 
This complex lacks E3 ubiquitin ligase activity. It is not known whether BRISC is related 
with the anti-apoptotic function of BRE.  
 
BRISC and BRCA1-A complexes are differentially regulated by protein-protein interactions 
in cytoplasm and nucleus, respectively. The abundance of one complex is counterbalanced in 
part by the abundance of the other complex (196). BRE is found critical for maintaining the 




Figure 1-9. BRE is expressed in cytosolic and nuclear compartments. (reproduced from 
reference (196)) 
 
1.6.4 The anti-apoptotic function of BRE 
1.6.4.1 In cell lines  
BRE is an anti-apoptotic protein in the extrinsic apoptotic pathway. BRE can bind to the 
intracellular domains of TNF-R1 and Fas. Besides, it can also conjugate with DISC complex 
during apoptosis (199, 212). The decreased apoptotic response to TNF-α and anti-Fas agonist 
antibody has been identified in Jurkat and HeLa cell lines when BRE is overexpressed. The 
increased apoptotic response to TNF-αhas been identified in HeLa cell line when BRE is 
knocked down by siRNA (199). 
 
BRE is also an anti-apoptotic protein in the intrinsic apoptotic pathway when cells are 
stimulated by stress-related and genotoxic stimuli. The decreased apoptotic response to 
cycloheximide (inhibitor of protein biosynthesis in eukaryotic organisms), 
4-nitroquinoline-1-oxide (DNA-damaging agent), etoposide (Topoisomerase II inhibitor), and 
staurosporine (broad-spectrum protein kinase inhibitor) has been observed when BRE is 
overexpressed (199). 
 
In contrast to tBID, which transfers the apoptotic signal from the extrinsic pathway to the 
mitochondrial pathway, BRE inhibits the crosstalk between the two pathways by inhibiting 
the release of pro-apoptotic mitochondrial proteins. BRE is not translocated to mitochondria 
or nucleus during apoptosis, and it does not affect the level of tBID (199). The anti-apoptotic 
function of BRE has been examined in CD95 type II cell line, such as HeLa, Jurkat, and 
hepatocyte. This type of cell line has a feature that it needs mitochondrial apoptotic pathway 
to amplify the apoptotic signal emanated from the death receptor (213, 214). 
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1.6.4.2 In vivo 
1.6.4.2.1 Human sample  
In a collection of 123 human hepatocellular carcinoma (HCC) samples, the tumoral regions of 
74% of these samples showed BRE overexpression. In contrast, little BRE was detected in the 
non-liver regions, cirrhotic regions or otherwise (198). Furthermore, the BRE overexpression 
levels correlated with poor differentiation of HCC and therefore poor prognosis (198).  
 
1.6.4.2.2 Mouse model 
The mouse Lewis lung carcinoma D122 stable transfectants of human BRE developed into 
local tumor faster than the stable transfectants of empty vector and parental D122. This was 
found in both syngeneic C57BL/6 host and nude mice in footpad injection model. However, 
in culture condition, the ectopic expression of human BRE in D122 does not affect cell 
proliferation (215). The anti-apoptotic function of BRE in vivo has been demonstrated by 
attenuation of Fas agonist antibody-induced acute fulminant hepatitis in transgenic mice 
expressing human BRE in the liver (198). Recent work on the transgenic mouse model shows 
significantly faster growth of diethylnitrosamine-induced liver tumors, but not the initiation of 
tumor formation. Of note, in the DEN-induced liver tumors of the control mice, the 
expression of endogenous BRE was also increased. This phenomenon indicates that BRE is 
important in the liver cancer (216). Taken together, BRE overexpression promotes tumor 
survival in liver instead of initiating tumor formation. BRE overexpression is not sufficient to 
initiate spontaneous tumor, but it can promote the growth of tumor by its anti-apoptotic 
activity. 
 
1.6.4.3 Seemingly opposing data 
A recent study showed that overexpression of BRE occurs predominantly in MLL-rearranged 
AML (acute myeloid leukemia) with a t(9;11)(p22;q23). Moreover, high BRE expression has 
been identified as an independent favorable prognostic factor for reduced cancer relapse in 
pediatric AML (217). Another study also reported correlation of high BRE expression with 
FAB M5 morphology and the MLL-AF9 fusion. This study demonstrated that high BRE 
expression predicts favorable outcome in adult acute myeloid leukemia, in particular among 
MLL-AF9–positive patients (218). These data seem to be contradictory with our reports that 
BRE attenuates apoptosis and promotes tumor survival. However, the above observations were 
based on microarray-based gene expression proﬁling and RT–PCR, which detect only the 
mRNA expression levels. Western blot analysis of BRE was carried out only by the first study 
which showed in fact no change in BRE protein expression between t(9;11)(p22;q23) (n=6) 
and other MLL-rearranged AML cases (n=5), despite the significant difference in mRNA 
expression levels found between the 2 groups. Owing to the contradictory findings between 
BRE mRNA and protein expression shown in the above study, further work is required to 
achieve a better understanding of the data reported in the 2 papers. 
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1.6.5 BRE and ubiquitin 
1.6.5.1.1 E3 and DUB functions of BRCA1-A complex 
BRCA1-A complex works as an E3 ubiquitin ligase (200). Rap80 recruits BRCA1-A to its 
K63-linked ubiquitin polymers tagged substrates at DSBs (204). BRE is necessary for the E3 
activity of BRCA1-A complex (200). BRCA1-A complex also possesses deubiquitinase 
activity that specifically removes K63-linked ubiquitin chains, rather than K6-, K11-, K29-, 
K48-, or linear-linked ubiquitin chains, on its substrates. BRCC36 in this complex processes 
this specificity (200-202). The substrates of BRCC36 include H2A/H2AX and some other 
unspecified yet non-histone substrates (188, 201, 211). RAP80 targets BRCC36 to its 
K63-linked polyubiquitinated substrates (208, 209). BRE may regulate the K63 DUB function 
of BRCC36 (201). This DUB function facilitates the complex to be released from the DSB 
sites once necessary repairs have been made (188). Taken together, BRCA1-A has both of 
ubiquitinating and deubiquitinating activities. The functions of DNA-repair and anti-apoptosis 
of BRCA1-A are regulated by amplifying and removing the ubiquitin chains (194). 
 
1.6.5.1.2 DUB function of BRISC 
BRISC also specifically cleaves K63-linked polyubiquitin chains, rather than K6-, K11-, K29-, 
K48- or linear-linked polyubiquitin chains, mainly due to BRCC36 (188). The K63-Ub 
substrate of BRISC is unknown (196). The DUB effect of BRISC towards its substrate only 
occurs to hydrophobic patch of the distal ubiquitin at a ubiquitin-ubiquitin cleavage site (219). 
Because ABRO1 lacks the BRCA1-interacting motif, the BRISC complex does not interact 
with BRCA1. Thus, BRISC lacks the E3 ubiquitin ligase activity (197). 
 
1.6.5.1.3 BRE  
The UEV domains of BRE enable it to bind ubiquitin (189, 194). BRE was shown to bind 
K48- and K63-linked polyubiquitin chains in vitro (194). Therefore, these domains of BRE 
may be involved in deubiquitinating activity of BRCC36 in the BRCA1-A and BRISC 
complexes. Furthermore, it is conceivable that the UEV domains may have a role in 
potentiating the E3 ligase activity of BRCA1/BARD1 in BRCA1-A complex (194, 196, 197). 
It is possible that the UEV domains of BRE may play a role in holding the polyubiquitin 
chains in an appropriate position (194). Furthermore, increased association of BRE with 
ubiquitinated proteins after death receptor stimulation was also detected. These results 
indicate that the anti-apoptotic function of BRE is closely related to ubiquitin (199). 
 
1.7 RNA interference 
1.7.1 Mechanism of RNA interference 
RNA interference (RNAi) is a process within living cells that moderates the activity of their 
genes. Two types of small ribonucleic acid (RNA) molecules, microRNA (miRNA) and small 
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interfering RNA (siRNA) are central to RNA interference. RNAs are the direct products of 
genes, and these small RNAs can bind to other specific messenger RNA (mRNA) molecules 
and either increase or decrease their activity, for example by preventing an mRNA from 
producing a protein. See Figure 1-10.  
 
The RNAi pathway is initiated by the enzyme Dicer, which cleaves long double-stranded 
RNA (dsRNA) molecules into short fragments of ~20 nucleotides. When the dsRNA is 
exogenous (coming from infection by a virus with an RNA genome or laboratory 
manipulations), the RNA is imported directly into the cytoplasm and cleaved to short 
fragments by the Dicer (220). The short fragments from the exogenous dsRNA are called 
siRNAs. The initiating dsRNA can also be endogenous (originating in the cell), as in 
pre-microRNAs expressed from RNA-coding genes in the genome. The primary transcripts 
from such genes are first processed to form the characteristic stem-loop structure of 
pre-miRNA in the nucleus, and then exported to the cytoplasm to be cleaved by Dicer. The 
cleaved fragments from endogenous dsRNA (pre-microRNA) are called mature miRNAs, 
which are structurally similar to siRNAs (221). 
 
Next, siRNA or mature miRNA is unwound into two single-stranded (ss) ssRNAs, namely the 
passenger strand and the guide strand. Here the double-stranded siRNA can derive from 
cleaved dsRNA or be transfected directly into cell. After the unwounding, the passenger strand 
is degraded, and the guide strand is incorporated into the RNA-induced silencing complex 
(RISC) (222). The most well studied outcome is post-transcriptional gene silencing, which 
occurs when the guide strand base pairs with a complementary sequence in a messenger RNA 
molecule and induces cleavage by Argonaute, the catalytic component of the RISC complex. 
Nowadays, RNAi has become a valuable research tool, both in cell culture and in living 
organisms, to induce suppression of specific genes of interest (223). 
 
1.7.2 Small hairpin RNA 
A small hairpin RNA or short hairpin RNA (shRNA) is a sequence of RNA that makes a tight 
hairpin turn that can be used to silence target gene expression via RNA interference (RNAi). 
shRNA is an advantageous mediator of RNAi in that it has a relatively low rate of degradation 
and turnover. Expression of shRNA in cells is typically accomplished by delivery of plasmids 
or through viral or bacterial vectors (224). Once the plasmids or vectors have integrated into 
the host genome, the shRNA is then transcribed in the nucleus by polymerase II or polymerase 
III depending on the promoter choice. This product mimics pre-microRNA (pre-miRNA) and is 
processed by Drosha. The pre-shRNA is exported from the nucleus by Exportin 5. This product 
is then processed by dicer and loaded into the RNA-induced silencing complex (RISC). The 
sense (passenger) strand is degraded. The antisense (guide) strand directs RISC to mRNA that 
has a complementary sequence. In the case of perfect complementarily, RISC cleaves the 
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mRNA. In the case of imperfect complementarily, RISC represses translation of the mRNA. In 
both of these cases, the shRNA leads to target gene silencing (225).  
 
 




CHAPTER 2: Materials and methods 
2.1 Materials 
2.1.1 Primers used for cloning 
All of primers were produced by Invitrogen. 
 
Table 2-1. Primers used for cloning 
Names Sequences 
V5For 
5’ GGG GAT CCG CCA CCA TGG CGA TCC CTA ACC CTC TCC 
TCG GTC TCG A 3’ 
V5Rev 
5’ GGG TCG ACC TAC GTA GAA TCG AGA CCG AGG AGA GGG 
TTA 3’ 
BREFor 
5’ GGG GAT CCG CCA CCA TGT CCC CAG AAG TGG CCT TGA A 
3’ 
BRERev 5’ GGG TCG ACC TAG AGC TTT CCA TTG GCA AAT GCT 3’ 
BREForAd 
5’ GGG GTA CCG CCA CCA TGT CCC CAG AAG TGG CCT TGA A 
3’ 
BRERevAd 5’ GGA AGC TTC TAG AGC TTT CCA TTG GCA AAT GCT 3’ 
V5ForAd 
5’ GGG GTA CCG CCA CCA TGG CGA TCC CTA ACC CTC TCC 
TCG GTC TCG A 3’ 
V5RevAd 
5’ GGA AGC TTC TAC GTA GAA TCG AGA CCG AGG AGA GGG 
TTA 3’ 
BREForEBB 5’ GGG GAT CCA TGT CCC CAG AAG TGG CCT TGA A 3’ 
BRERevEBB 5’ GGG CGG CCG CTA GAG CTT TCC ATT GGC AAA TGC T 3’ 
 
2.1.2 DNA clones used in the studies 
1. pBABEpuro, pBABEpuro-BRE, pBABEpuro-BREV5, pBABEpuro-V5BRE 
pBABEpuro is a mammalian expression, retroviral expression vector from Addgene (#1764) 
(Figure 2-1). It has a puromycin selectable marker. Three targets (BRE, BRE tagged by V5 at 
the C-terminus, BRE tagged by V5 at the N-terminus) were cloned into pBABEpuro 
separately, via the cloning sites of Sal I and BamH I, generating three pBABEpuro-based 
retroviral expression vectors, which were named as pBABEpuro-BRE, pBABEpuro-BREV5, 
and pBABEpuro-V5BRE. These retroviral expression vectors were used with the retroviral 




Figure 2-1. Map of pBABEpuro (reproduced from reference (48)) 
 
2. pBABEneo, pBABEneo-BREV5 
pBABEneo is a mammalian expression, retroviral expression vector from Addgene (#1767) 
(Figure 2-2). It has a neomycin selectable marker. One target (BRE tagged by V5 at the 
C-terminus) was cloned into pBABEneo, via the cloning sites of Sal I and BamH I, generating 
a pBABEneo-based retroviral expression vector, which was named as pBABEneo-BREV5. 




Figure 2-2. Map of pBABEneo (reproduced from reference (48)) 
 
3. pBABEhygro, pBABEhygro-BRE 
pBABEhygro is a mammalian expression, retroviral expression vector from Addgene (#1765) 
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(Figure 2-3). It has a hygromycin selectable marker. One target (BRE) was cloned 
pBABEhygro via the cloning sites of Sal I and BamH I, generating a pBABEhygro-based 
retroviral expression vector, which was named as pBABEhygro-BRE. pBABEhygro-BRE 
was used with the retroviral package vector, pCL-Ampho to generate retrovirus. 
 
 
Figure 2-3. Map of pBABEhygro (reproduced from reference (48)) 
 
4. pCL-Ampho 
pCL-Ampho is a retroviral package vector, commercially available from Imgenex (#10046P). 
It is safety-modified and can express a high-level expression of gap, pol, and env proteins. It 
is suitable for most mammalian cells (but not hamster). It was used for retrovirus generation 
together with retroviral expression vectors, such as pBABEpuro, pBABEpuro-BRE, 
pBABEpuro-BREV5, pBABEpuro-V5BRE, pBABEneo-BREV5, and pBABEhygro-BRE. 
 
 
Figure 2-4. Structure of pCL-Ampho (reproduced from reference (226)) 
 
5. pAdTrack-CMV, pAdTrack-CMV-BRE, pAdTrack-CMV-BREV5, 
pAdTrack-CMV-V5BRE 
pAdTrack-CMV is a mammalian expression, adenoviral shuttle vector in the AdEasy system, 
which is for adenovirus generation, commercially available from Addgene (#16405) (Figure 
2-5). It has a kanamycin selectable marker and a GFP monitor. Three targets (BRE, BRE 
tagged by V5 at the C-terminus, BRE tagged by V5 at the N-terminus) were cloned into 
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pAdTrack-CMV separately, via the cloning sites of Kpn I and Hind III, generating three 
pAdTrack-CMV-based adenoviral shuttle vectors, which were named as 
pAdTrack-CMV-BRE, pAdTrack-CMV-BREV5, and pAdTrack-CMV-V5BRE. Recombinant 
of pAdTrack-CMV-BREV5 and pAdEasy®-1 was used for adenovirus generation. 
 
 
Figure 2-5. Map of pAdTrack-CMV (reproduced from reference (48)) 
 
6. pAdEasy®-1 
It is a mammalian expression, adenoviral backbone vector in the AdEasy system, which is for 
adenovirus generation, commercially available from Addgene (#16400) (Figure 2-6). It has an 
ampicillin selectable marker. Recombination occurred between the adenoviral backbone 
vector (pAdEasy®-1) and the adenoviral shuttle vector containing BRE tagged by V5 at the 
C-terminus (pAdTrack-CMV-BREV5). This recombinant was packaged into HEK293T cells 
to make adenovirus. Besides, the AdEasier®-1 bacterial cells are BJ5183 derivatives, which 
already contain this pAdEasy®-1 plasmid.  
 
 
Figure 2-6. Map of pAdEasy®-1 (reproduced from reference (48)) 
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7. pcDNA3 and V55K 
pcDNA3 is a mammalian expression vector, commercially available from Invitrogen (Figure 
2-7). It contains a neomycin selectable marker. It was used as a vehicle control in gene 
transfection. In V55K, BRE tagged with V5 at the N-terminus was cloned into pcDNA3 
vector. V55K was used as PCR template for the insert containing BRE tagged with V5 at the 
N-terminus. This V5BRE insert was cloned into pBABEpuro to generate a pBABEpuro-based 
retroviral expression vector, which was named as pBABEpuro-V5BRE. Similarly, this 
V5BRE insert was cloned into pAdTrack-CMV to generate a pAdTrack-CMV-based 
adenoviral shuttle vector, which was named as pAdTrack-CMV-V5BRE. 
 
 
Figure 2-7. Map of pcDNA3 (reproduced from reference (40)) 
 
8. pEBB-FLAG-XIAP and pEBB-FLAG-BRE 
pEBB-FLAG-XIAP is a pEBB-based mammalian expression vector containing full length 
of XIAP tagged by FLAG, commercially available from Addgene (#11558) (Figure 2-8). 
The backbone size of pEBB is 5353 bp, while the size of the insert (XIAP tagged by 
FLAG) is 1500 bp. It contains a neomycin selectable marker. It was used for high level of 
XIAP expression. Besides, XIAP in pEBB-FLAG-XIAP was replaced by BRE to generate 
a pEBB-based plasmid, which can express high level of BRE. This pEBB-based plasmid, 




Figure 2-8. Map of pEBB-FLAG-XIAP (reproduced from reference (48)) 
 
9. pcDNA3.1/GS and GS-BRE 
pcDNA3.1/GS is a Gene Storm® empty vector, commercially available from Invitrogen 
(#H-K1000) (Figure 2-9). GS-BRE, ResGen Gene Storm® Clone for accession number 
L38616, was purchased from Invitrogen. In GS-BRE, BRE tagged with V5 and 6x His at the 
C-terminus was cloned into the pcDNA3.1/GS empty vector. GS-BRE was used as PCR 
template for the inserts containing BRE alone and BRE tagged with V5 at the C-terminus. 
These inserts were cloned into pBABEpuro, pBABEneo, and pBABEhygro separately, to 
generate pBABEpuro-BRE, pBABEpuro-BREV5, pBABEneo-BREV5, and 
pBABEhygro-BRE for retrovirus generation. Similarly, these inserts were cloned into 
pAdTrack-CMV separately to generate pAdTrack-CMV-based adenoviral shuttle vectors, 
which were named as pAdTrack-CMV-BRE and pAdTrack-CMV-BREV5. GS-BRE was also 
used as PCR template for the insert containing BRE alone to generate the pEBB-based 
plasmid, pEBB-FLAG-BRE, which can express high level of BRE. Besides, pcDNA3.1/GS 
and GS-BRE were used to generate stable transfectants of Jurkat A3 cell, which were named 




Figure 2-9. Map of pcDNA3.1/GS (reproduced from reference (41)) 
 
10. pRK5-HA-Ubiquitin-K48 
pRK5-HA-Ubiquitin-K48 is a pRK5-HA-based mammalian expression vector containing 
K48 only ubiquitin with all of the other lysines mutated to arginines, commercially 
available from Addgene (#17605). The backbone size of pRK5-HA is 4800 bp, while the 
size of the insert (K48 ubiquitin) is 220 bp. It was used for high level HA tagged 
K48-linked ubiquitin expression. 
 
 
Figure 2-10. Map of pRK5-HA-Ubiquitin-K48 (reproduced from reference (48)) 
 
11. pRK5-HA-Ubiquitin-K63 
pRK5-HA-Ubiquitin-K63 is a pRK5-HA-based mammalian expression vector containing 
K63 only ubiquitin with all of the other lysines mutated to arginines, commercially 
available from Addgene (#17606). The backbone size of pRK5-HA is 4800 bp, while the 
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size of the insert (K63 ubiquitin) is 220 bp. It was used for high level HA tagged 
K63-linked ubiquitin expression. 
 
 
Figure 2-11. Map of pRK5-HA-Ubiquitin-K63 (reproduced from reference (48)) 
 
12. pRK5-HA-Ubiquitin-K0 
pRK5-HA-Ubiquitin-K0 is a pRK5-HA-based mammalian expression vector containing 
K0 ubiquitin with all of the lysines mutated to arginines, commercially available from 
Addgene (#17603). The backbone size of pRK5-HA is 4800 bp, while the size of the 




Figure 2-12. Map of pRK5-HA-Ubiquitin-K0 (reproduced from reference (48)) 
 
13. BRE shRNA and empty shRNA vector 
Empty shRNA vector is negative control shRNA pGFP-V-RS non-effective tGFP plasmid, 
 44 
commercially available from Origene (#TR30008) (Figure 2-13). It contains kanamycin and 
puromycin resistance markers for easy selection. BRE shRNA is shRNA construct against 
Mus musculus BRE in pGFP-V-RS vector, from Origene (#GI536607). The sequence against 
BRE is CAT CTT TGG AGA GGA TGC TGA GTT TCT GC. BRE shRNA and empty shRNA 
were cloned into the pGFP-V-RS vector under U6 polymerase III promoter for shRNA 
expression, respectively. BRE shRNA was used to generate stable BRE-depleted cell lines of 
D122, which were named as B07. Empty shRNA vector was used to generate negative control 
cell lines of D122, which were named as T8. 
 
 
Figure 2-13. Map of pGFP-V-RS (reproduced from reference (44)) 
 
2.1.3 Materials for DNA manipulation 
 
Table 2-2. Materials for DNA manipulation 
Chemicals and enzymes Manufactures 
Platiunm® pfx DNA polymerase 
dNTP 
10 pfx amplification buffer 
MgSO (50 mM)
T4 DNA ligase 
T4 DNA ligase buffer 
DNA MW marker (1 kb plus) 
Invitrogen (Carlsbad, CA) 
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Quick-Load® DNA ladder (1 kb, 100 bp) 
Restriction enzyme and buffer 
New England Biolabs (Beverly, MA) 
CHROMA SPIN
 TM
-1000 column Clontech Laboratories (Palo Alto, CA) 
Glycerol Sigma (St. Louis, MO) 
SeaKem® LE agarose 
Cambrex Bio Science Rockland (Rockland, 
ME) 
 
2.1.4 Materials for protein manipulation 
 
Table 2-3. Materials for protein manipulation 
Materials Manufactures 
rec-Protein G-Sepharose® 4B conjugate Invitrogen (Camarillo, CA) 
1 cell lysis buffer (#9803) Cell Signaling (Danvers, MA) 
Complete mini EDTA-free protease inhibitor 
cocktail tablet 
Phosphatase inhibitor cocktail tablet 
Roche (Mannheim, Germany) 
Phenylmethanesulfonyl fluoride (PMSF) 
Trizma® base 
Sodium chloride 
Ethylene diamine tetraacetic acid (EDTA) 
Triton X-100 
Glycine 
Sodium dodecyl sulfate (SDS) 
PBS 
TWEEN® 20 
Ammonium persulfate (APS) 
Sigma (St. Louis, MO) 
30% Acrylamide/Bis solution 
Immun-Blot
TM
 PVDF membrane (0.2 µm) 
Bio-Rad Laboratories (Hercules, CA) 
Methanol 
Isopropanol 
Merk (Darmstadt, Germany) 
Lumingen
TM
 PS-3 detection reagent 
Lumingen
TM 
TMA-6 detection reagent 
Amersham hyperfilm
TM ECL high 
performance chemiluminescence film
ECL advance blocking milk 




 prestained protein molecular 
weight ladder 
Fermentas (Ontario, Canada) 
Calcium plus skimmed milk Nestle (Vevey, Switzerland) 
 
2.1.5 Materials for virus manipulation 
 
Table 2-4. Materials for virus manipulation 
Materials Manufactures 
Sodium chloride 




Sigma (St. Louis, MO) 
100% ethanol Merk (Darmstadt, Germany) 
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Nucleic acid purification grade, 
phenol/water/chloroform 
Applied Biosystems (Foster City, CA) 
Pellet paint co-precipitant  EMD Chemicals (San Diego, CA) 
E.coli pulser cuvette (0.1 cm electrode gap) BIO-RAD Laboratories (Hercules, CA) 




Table 2-5. Antibodies 
Antibodies Manufactures Catalog # 
Anti-GAPDH US-Biological (Swampscott, MA) G8140-11A 
Anti-β-actin AC-74 
HRP-anti-HA  H6533 
HRP-anti-FLAG  A8592 
Anti-FLAG 
Sigma (St. Louis, MO) 
F3165 
Anti-biotinylated XIAP R&D (Minneapolis, MN) BAF8221 
Anti-cFLIP 3210 




Anti-cleaved caspase 3 
Cell Signaling (Danvers, MA) 
9661S 
Anti-cIAP-1 IMGENEX (San Diego, CA) IMG-5716 
Anti-cIAP-2 R&D (Minneapolis, MN) MAB817 
HRP-anti-V5  Invitrogen (Camarillo, CA) 46-0708 
Anti-XIAP 




Anti-Mouse Ig-HRP 554002 
Streptavidin-HRP 




Clinical Immunology Laboratory, 
CUHK Mab246 




Table 2-6. Chemicals 
Chemicals  Manufactures 




Sigma (St. Louis, MO) 
Caspase family inhibitor, Z-VAD-FMK 
(VAD) 
BIovision (Mountain View, CA) 






Table 2-7. Kits 
Kits Manufactures 
BCA protein assay kit Pierce (Rockford, IL) 
Plasmid miniprep kit 
Plasmid midiprep kit 
QIAquick gel extraction kit 
Qiagen Inc. (QIAGEN GmbH, Hilden) 
Annexin V-PE apoptosis detection kit BD Phamingen (San Diego, CA) 
Platiunm® pfx DNA polymerase kit 
T4 DNA ligase kit 
Invitrogen (Carsbad, CA) 
LumingenTM PS-3 detection kit
LumingenTM TMA-6 detection kit
GE healthcare (little Chalfont, 
Buckinghamshire, UK) 
 
2.1.9 Culture media and reagents 
 














Sigma (St. Louis, MO) 
Zeocin 
Lipofectamine 2000 
Invitrogen (Carlsbad, CA) 
Ampicillin sodium  Medochemie Ltd. (Limassol, Cyprus) 
 
2.1.10  Bacterial strains used for transformation and 
cloning 
TOP 10 E. coli 
DH5α 
AdEasier®-1: they are BJ5183 derivatives, which already contain the AdEasy®-1 plasmid.  
 
2.1.11  Instrumentation 
 
Table 2-9. Instrumentation 
Instruments Manufactures 
Thermal Cyclers PTC-200 MJ research, Inc. (South San Francisco, CA) 
Thermal Cyclers C1000 BIO-RAD Laboratories (Hercules, CA) 
FAScan Calibur Becton Dickinson (Franklin Lakes, NJ) 
Platform Vari Mix Shaker 
Type 37600 mixer 
Barnstead/Thermolyne (Dubuque, IA) 
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MIRAKTM digital 4 place Multi Mixer
Model 200/2.0 power supply 
Mini-PROTEAN® Tetra cell 
Trans-Blot® SD Semi-dry transfer cell 
BIO-RAD Laboratories (Hercules, CA) 
Power supply for Gel Electrophoresis 
Chamber 
Pharmacia (little Chalfont, Buckinghamshire, 
UK) 
FOTODYNE Gel Electrophoresis Chamber 
FOTODYNE FotoDyne Phoresis I 
FOTODYNE 5-5334 
FOTODYNE exposer 
Carolina Biological Supply Company 
(Burlington, NC) 




BIO-RAD Laboratories (Hercules, CA) 
Inverted microscope Olympus (Tokyo, Japan) 
Fluorescence microscope DMIRB Leica Microsystems (Wetzlar, Germany) 
Centrifuge 5415D 
Centrifuge 5424 
Eppendorf (Hamburg, Germany) 
Centrifuge J6-MI 
Centrifuge Avanit J-25I 
Beckman Coulter (Fullerton, CA) 
Centrifuge Multifuge X3R Thermo Fisher Scientific (Billerica, MA) 
DU® 800 spectrophotometer 
DTX 800 Multimode Detector 
Beckman Coulter (Fullerton, CA) 
NanoDrop® ND-1000 Spectrophotometer Thermo Fisher Scientific (Billerica, MA) 
Balance TE3102S Sartorius (Bradford, MA) 
Electronic balance ER-180A A&D (San Jose, CA) 
GEMINI twin shaking water bath Robbins Scientific (Billerica, MA) 
Water bath Clifton company (Clifton, NJ) 
Haake Heating Circulator Haake (Overland Park, KS) 
BINDER constant temperature incubator BINDER Inc. (Bohemia, NY) 
Water Jacked CO2Incubator Forma Scientific (Billerica, MA) 
Orion 2 star PH Bench top detector Thermo Fisher Scientific (Billerica, MA) 
OPTIMAX X-Ray film Processor Optimax Company (Oberstenfeld, Germany) 
 
2.2 Methods 
2.2.1 Construction of plasmids 
2.2.1.1 Polymerase chain reaction (PCR) 
 
Table 2-10. Reaction mixer for PCR 
Names Volumes 
10× pfx amplification buffer 5 µl 
MgSO4 (50 mM) 1 µl 
dNTP (2.5 mM) 6 µl 
Primer 1 (10 pmol/µl) 1 µl 
Primer 2 (10 pmol/µl) 1 µl 
H2O 34.6 µl 
Template (50 ng/µl) 1 µl 
Platiunm® pfx DNA polymerase 0.4 µl 
Total volume 50 µl 
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Table 2-11. Cycling parameters for PCR 
Segments Number of cycles Temperature (ć) Duration 
1 1 94 3 min 





68 2 min 
3 1 68 5 min 
4 1 12 Forever 
 
Nine constructs were prepared for later usage. The differences of their inserts in PCR 
manipulation were as follows. 
 
Table 2-12. Differences of inserts of nine constructs in PCR manipulation 





BREFor BRERev 63ć 
pBABEpuro-BREV5 GS-BRE
 
BREFor V5Rev 65ć 
pBABEpuro-V5BRE V55K V5For BRERev 63ć 
pBABEneo-BREV5 GS-BRE BREFor V5Rev 65ć 
pBABEhygro-BRE GS-BRE BREFor BRERev 63ć 
pAdTrack-CMV-BRE GS-BRE BREForAd BRERevAd 63ć 
pAdTrack-CMV-BREV5 GS-BRE BREForAd V5RevAd 65ć 
pAdTrack-CMV-V5BRE V55K V5ForAd BRERevAd 63ć 
pEBB-FLAG-BRE GS-BRE BREForEBB BRERevEBB 63ć 
 
2.2.1.2 Enzyme digestion and purification 
PCR products were purified by agarose gel electrophoresis, using the QIAquick gel extraction 
kit according to the manufacture’s instruction. The purified PCR products and corresponding 
vectors were digested by enzymes according to the cloning sites. The digestion condition was 
set according to the manufacture’s instruction. After digestion, the digested insert was purified, 
using the QIAquick gel extraction kit according to the manufacture’s instruction. The digested 
vector was purified by CHROMA SPIN
 TM
-1000 column according to the manufacture’s 
instruction or by agarose gel electrophoresis, using the QIAquick gel extraction kit. The 
differences of the nine constructs in enzyme digestion manipulation were as follows. 
 
Table 2-13. Differences of nine constructs in enzyme digestion manipulation 
























































pEBB-FLAG-BRE Not I and 
BamH I 





Table 2-14. Ligation condition 
Names Conditions 
× T4 DNA ligase buffer 4 µl 
Purified digested insert 100 ng 
Purified digested vector 100 ng 
T4 DNA ligase (5 U/µl) 1 µl 
H2O To 20 µl 
Total volume 20 µl 
Temperature  14ć 
Time  Overnight 
 
2.2.1.4 Heat shock transformation 
Five µl of ligation product was added into an eppendorf containing 50 µl of competent cells 
(DH5α). The eppendorf was incubated in ice for 30 min. Then it was incubated in 42ć water 
bath for 30 sec and then on ice for 2 min. Two hundred and fifty µl of LB medium was add 
into the cells. The eppendorf was shaked at 37ć at 250 rpm for 1 hour. LB plates containing 
100 µg/ml of ampicillin or 50 mg/ml of kanamycin were pre-warmed to room temperature. All 
of the bacteria were spreaded on these antibiotic-containing plates. Then the plates were 
incubated at 37ć for overnight. 
 
Table 2-15. Differences of nine constructs in heat shock transformation 
Names of constructs Antibiotics 
pBABEpuro-BRE Ampicillin (100 µg/ml) 
pBABEpuro-BREV5 Ampicillin (100 µg/ml) 
pBABEpuro-V5BRE Ampicillin (100 µg/ml) 
pBABEneo-BREV5 Ampicillin (100 µg/ml) 
pBABEhygro-BRE Ampicillin (100 µg/ml) 
pAdTrack-CMV-BRE Kanamycin (50 mg/ml) 
pAdTrack-CMV-BREV5  Kanamycin (50 mg/ml) 
pAdTrack-CMV-V5BRE Kanamycin (50 mg/ml) 
pEBB-FLAG-BRE Ampicillin (100 µg/ml) 
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2.2.1.5 Check of plasmids 
Several single colonies of bacteria on the antibiotic-containing plates were collected for PCR 
check and miniprep separately. The plasmids of miniprep were used for digestion check. The 
colony whose PCR check and digestion check were both positive was picked to prepare 
midiprep. The concentration of plasmids was measured by NANODrop and confirmed by 
agarose gel electrophoresis. Then the plasmids of midiprep were sent for sequencing. cDNA 
and amino acid sequences of gene of interests of the nine constructs were as follows.  
 
Table 2-16. cDNA and amino acid sequences of gene of interests of the nine constructs 





BREV5 (BRE tagged by V5 
at the C-terminus) 
Figure 2-15 
pBABEpuro-V5BRE 
V5BRE (BRE tagged by V5 
at the N-terminus) 
Figure 2-16 
pBABEneo-BREV5 
BREV5 (BRE tagged by V5 
at the C-terminus) 
Figure 2-15 
pBABEhygro-BRE BRE Figure 2-14 
pAdTrack-CMV-BRE BRE Figure 2-14 
pAdTrack-CMV-BREV5  
BREV5 (BRE tagged by V5 
at the C-terminus) 
Figure 2-15 
pAdTrack-CMV-V5BRE 
V5BRE (BRE tagged by V5 
at the N-terminus) 
Figure 2-16 




































































 Figure 2-15. cDNA and amino acid sequences of BREV5 



































Figure 2-16. cDNA and amino acid sequences of V5BRE 
Sequence of BRE is shown in underlined letters. Sequence of V5 epitope is shown in bold. 
 
2.2.2 Plasmids preparation 
When preparing plasmids initially from the stab culture, several single colonies were isolated 
first. Then the sterile liquid LB containing the suitable antibiotic (100 µg/ml of ampicillin or 
50 mg/ml of kanamycin), according to the antibiotic resistant gene of the plasmid, was 
prepared. One single colony was transferred into 100 ml of liquid LB containing the suitable 
antibiotic by using a sterile pipette tip. Bacterial culture was shaked for around 16 hours at 
250 rpm in a 37ć shaking incubator. After that, 900 µl of bacterial culture was aspirated into 
250 µl of sterile 80% Glycerol as long term storage, which was kept in a -80ć freezer. The 
plasmids in the left bacterial culture were extracted using a Qiagen midiprep kit. When 
preparing plasmids, whose long term storage was already prepared, a few bacteria were 
picked from the -80ć long term storage into 100 ml of liquid LB containing suitable 
antibiotic by using a sterile pipette tip. The latter steps were the same with the 
above-mentioned steps. 
 
2.2.3 Cell culture 
2.2.3.1 Monolayer cells  
 
Table 2-17. Monolayer cells 
Names  Descriptions Catalog # 













The poorly immunogenic and highly metastatic D122 




BRE-depleted cell line of D122 with stable BRE shRNA 
(#GI536607, Origene) transfection.  
/ 
E7, C6 Subclone of B07 cell line / 
T8 
Negative control cell line of D122 with stable empty 
shRNA vector (#TR30008, Origene) transfection.  
/ 
C6-neo-BREV5 




These cells were grown in DMEM medium supplemented with 10% fetal bovine serum and 
100 U/ml of penicillin and streptomycin. Cultures were maintained at 37ć with 5% CO2. 
 
2.2.3.2 Suspension cell 
 
Table 2-18. Suspension cells 
Names  Descriptions Catalog # 
Jurkat A3 
Human acute T cell leukemia subclone selected for high 




Jurkat A3 with stable empty vector pcDNA3.1/GS 
transfection 
/ 
GSB2 Jurkat A3 with stable GS-BRE transfection / 
 
The cells were grown in RPMI medium supplemented with 10% fetal bovine serum and 100 
U/ml of penicillin and streptomycin. Cultures were maintained at 37ć with 5% CO2. 
 
2.2.4 Cell transfection 
Cells, such as D122, C6, and HEK293T, were washed twice in the DMEM with 10% fetal 
bovine serum only. Appropriate number of cells (usually 2 × 10
5
 cells for D122 and C6, 1 × 
10
6
 cells for HEK293T) were seeded in one well of a 6-well plate. After overnight incubation, 
cells were around 80-90% confluent. The cells were washed twice in DMEM only. Two ml of 
DMEM only was added to the cells as plating medium. Four µg of DNA was diluted in 250 µl 
of Opti-MEM® I medium. Ten µl of Lipofectamine 2000 was diluted in another 250 µl of 
Opti-MEM® I medium. The diluted Lipofectamine 2000 was incubated for 5 min at room 
temperature. The diluted DNA was combined with the diluted Lipofectamine 2000 by gently 
mixing. The mixture was incubated for 20 min at room temperature. Five hundred µl of 
DNA-Lipofectamine complexes were added to the well. Cells were incubated after a gentle 
mix. After 4 to 6 hours, medium containing DNA-Lipofectamine complexes was changed 
with serum- and penicillin/streptomycin-containing fresh DMEM medium. Forty-eight hours 
after transfection, cells were used for further analysis. 
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For performing transfection in a 25-cm
2
 flask to generate adenovirus, 2 × 10
6
 HEK293T cells 
were seeded. Three ml of DMEM only was added to the cells as plating medium. Four µg of 
DNA was diluted in 500 µl of Opti-MEM® I medium. Twenty µl of Lipofectamine 2000 was 
diluted in 500 µl of Opti-MEM® I medium. The other details were the same with the 
above-mentioned steps. 
 
2.2.5 Generation of stable transfectants 
One day before transfection, 2 × 10
5
 D122 cells per well were seeded in two wells of a 6-well 
plate,. After overnight incubation, they were transfected with BRE and negative control 
shRNA, respectively. Twenty-four hours after transfection, cells in each well were trypsinized 
and resuspended in 24 wells of a 24-well plate with medium containing 5 µg/ml of puromycin. 
Around 10 days later, the puromycin resistant cells in each well of the 24-well plate were 
trypsinized and resuspended in one well of a 6-well plate. Cells were harvested for check 
when they were around 80-90% confluent. The expression level of target gene was checked 
by Western blot analysis. Cell lines of D122 with stable BRE shRNA and empty shRNA 
transfection were named as B07 and T8, respectively. 
 
2.2.6 Western blot analysis 
2.2.6.1 BCA™ protein assay 
A set of diluted albumin standards and BCA™ working reagents were prepared according to 
the manufacture’s instruction. The sample, whose protein concentration was unknown, was 
diluted. BCA™ working reagents were added to the diluted albumin standards and the diluted 
sample. They were incubated at 37ć for 30 min. The absorbance values of them at 595 nm 
were tested by the DTX 800 multimode detector. The protein concentration of the sample was 
calculated according to the relationship between the protein concentrations and absorbance 
values of the albumin standards. 
 
2.2.6.2 SDS-PAGE 
The same quantities of samples (5 µg or 10 µg) were resolved on 9% sulphate-polyacrylamide 
gel. Electrophoresis was carried out at 85 V at room temperature. The gel was calibrated with 
protein marker. After electrophoresis, protein was transferred onto PVDF membrane using a 
Semi-Dry transferring cell at 20 V for 30 min. 
 
2.2.6.3 Immunoblotting  
The PVDF membrane containing the transferred protein was blocked for 2 hours at room 
temperature. The blocking powder was dissolved in TBS. Primary antibody was then added to 
the membrane. After overnight incubation with shaking, the membrane was subsequently 
washed with PBST (PBS, 0.05% Tween-20) for three times at 10 minutes each. The bound 
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primary antibody was visualized with appropriate HRP-conjugated secondary antibody for 3 
hours. Lumingen detection reagent was applied to the membrane. Then the membrane was 
exposed to X-ray film. The following table showed the details of the blocking milk, 
antibodies, and detection reagents. M meant calcium plus skimmed milk. EM meant ECL 
advance blocking milk. 
 














Ig-HRP (in 2% M) 
PS-3 




Ig-HRP (in 2% M) 
PS-3 





















Ig-HRP (in 5% M) 
TMA-6 












Ig-HRP (in 5% M) 
TMA-6 




Ig-HRP (in 5% M) 
TMA-6 
Anti-cIAP-2 2% M 
1:4000 (in 
2% EM) 
1:30000 Anti-Mouse (in 
2% M) 
TMA-6 




Anti-XIAP 2% M  
1:4000 (in 
2% EM) 
1:30000 Anti-Mouse (in 
2% M) 
TMA-6 
Anti-ubiquitin 2% M  
1:4000 (in 
2% EM) 





2% M  
1:10 (in 2% 
EM) 





2% M  
1:5 (in 2% 
EM) 




2.2.7 Chemical treatment  
2.2.7.1 Etoposide, TNF-α, MG132, CHX, VAD, and DMSO 
For monolayer cells: 
(1) Direct treatment of monolayer cells  
One day before chemical treatment, 2 × 10
5
 cells, such as D122, C6, E7, T8, and 
C6-neo-BREV5 were seeded in one well of a 6-well plate. Around 16 hours later, culture 
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medium of cells was changed to 3 ml of fresh medium containing suitable chemical, such as 
etoposide, TNF-α, MG132, CHX, VAD, and solvent control DMSO. Cells were incubated 
with the chemical containing medium for the indicated time. After that, they were harvested 
for further analysis. 
(2) Treatment of monolayer cells after transfection 
Forty-eight hours after transfection, culture medium of cells, such as C6 and HEK293T, was 
changed to 3 ml of fresh medium containing suitable chemical, such as TNF-α, MG132, and 
solvent control DMSO. The latter steps were the same with (1). 
 
For suspension cells: 
Two hundred thousand cells, such as GSV1 and GSB2 in 3 ml of fresh medium containing 
suitable chemical, such as etoposide, MG132, VAD, and solvent control DMSO, were seeded 
in one well of a 6-well plate. The cells were incubated with the chemical containing medium 
for the indicated time. After that, they were harvested for further analysis. 
 
2.2.7.2 NEM  
In NEM treatment experiments, NEM was used in the following two ways: 
(1) Addition of NEM into lysis buffer for subsequent cell lysis  
Before cell harvest, NEM was added to fresh routine lysis buffer (Cell Signaling, #9803). 
Cells were lysed by this NEM-containing lysis buffer and routine lysis buffer separately. 
(2) Addition of NEM to cell lysate 
Cells were lysed in routine lysis buffer (Cell Signaling, #9803) first. Protein concentration of 
this lysate was tested. The same quantities of proteins (5 µg) were allocated to several 
eppendorfs. NEM was added into some of these eppendorfs. H2O was added into one 
eppendorf as solvent control. There was another eppendorf with nothing added into it as 
negative control. These eppendorfs were incubated in ice for 10 min. Next, they were 
vortexed for 10 sec and rotated on a rolling platform for 1 hour at 4ć. After that, these 
eppendorfs were centrifuged at 13200 rpm for 10 min at 4ć. Then they were used for 
Western blot analysis. 
 
2.2.8 Apoptosis assays by the flow cytometry 
BRE-depleted cells, B07 and negative shRNA control line, T8 were treated with TNF-α in the 
absence of cycloheximide for the indicated time duration. Cells were harvested for flow 
cytometric analysis using Annexin V-FITC and Propidium Iodide staining. Cells were 
trypsinized and washed twice with ice-cold PBS. Next, cells were pelleted by centrifuge at 
1000 rpm for 5 min at 4ć, and then resuspended in 100 µl of × binding buffer. Five µl of 
Annexin V-FITC and 5 µl of Propidium Iodide were added into the solution. Solution was 
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mixed gently and incubated for 15 min at room temperature in dark. Four hundred µl of 1× 
binding buffer was added to the solution. Flow analysis was conducted using FACS Calibur 
flow cytometry and CellQuest software. 
 
2.2.9 Immunoprecipitation 
Around 2 ×106 cells were harvested. Cells were washed twice with 1 ml of PBS in an 
eppendorf and spinned at 4000 rpm for 1 min. Next, supernatant was removed completely and 
cell pellet was resuspended in 0.5 ml of ice-cold IP lysis buffer (20 mM Tris PH 7.4, 50 mM 
NaCl, 2 mM EDTA, 1 mM PMSF, × protease inhibitor cocktail, 1× phosphatase inhibitor 
cocktail, 1% Triton X-100, 5 µM MG132). The eppendorf was vortexed gently, and placed on 
a rolling platform for 1 hour at 4ć. After centrifuge at 3000 rpm for 15 min, supernatant was 
carefully collected without disturbing the pellet, and transferred to a clean eppendorf. Protein 
concentration was measured by BCA assay. A total of 200 µg of each sample was transferred 
to a new eppendorf and pre-cleared with 20 µl of Protein G-Sepharose for 1 hour. Then beads 
were pelleted by centrifuge 10,000 g for 1 min and supernatant was removed to another new 
eppendorf. Five µg of antibody was added to each eppendorf containing lysate. The eppendorf 
was placed on a rolling platform at 4ć for 1 hour. Fifty µl of washed Protein G-Sepharose in 
pre-chilled lysis buffer was added into each eppendorf. The mixture was continually 
incubated on a rolling platform at 4ć for overnight. After incubation, the eppendorf was 
centrifuged at 10000 g for 2 min at 4ć. The supernatant was removed completely and the 
beads were washed 5 times with 400 µl of lysis buffer each. After the last wash, supernatant 
was aspirated. Seven point five µl of × SDS loading buffer (200 mM Tris-HCl pH 6.8, 8% 
SDS, 40% glycerol, 4% β-mercaptoethanol, 50 mM EDTA, 0.08% bromophenol blue) and 
22.5 µl of IP lysis buffer were added to the beads. Beads were vortexed and heated to 100 ć 
for 5 min. Then beads were pelleted by centrifuge at 10000 g for 5 min. Supernatant, 
considered as elute, was collected to load onto the gel. 
 
2.2.10  BRE containing retrovirus generation and 
transduction 
2.2.10.1 Retrovirus generation 
2.2.10.1.1 Production of retrovirus by transient transfection of 
packaging cells 
Five pBABE-based retroviral expression vectors containing gene of BRE were generated 
according to a standard molecular cloning procedure. The retrovirus was named after the 




Table 2-20. Retroviral expression vectors and corresponding retrovirus 
Names of retroviral 
expression vectors 


















BRE tagged by V5 at 
the C-terminus 
Neomycin pBABEneo-BREV5 
pBABEhygro-BRE BRE Hygromycin pBABEhygro-BRE 
 
HEK293T cells were co-transfected with one of the above-mentioned retroviral expression 
vector containing the gene of BRE and the retroviral package vector, pCL-Ampho. 
Forty-eight h after the transfection, retrovirus-containing supernatant was harvested. It was 
filtered by 0.45 mm syringe filters. After that, any cells in the supernatant were removed. The 
retrovirus-containing supernatant was used directly or stored at -80ć. 
 
2.2.10.1.2 Production of retrovirus by stable transfection of 
packaging cells 
HEK293T cells were co-transfected with one of the above-mentioned retroviral expression 
vector containing the gene of BRE and the retroviral package vector, pCL-Ampho. 
Forty-eight h after the transfection, cells were selected according to the selectable marker of 
the retroviral expression vector (Table 2-20). Five µg/ml of puromycin was used for 
pBABEpuro-BRE, pBABEpuro-BREV5, and pBABEpuro-V5BRE, 2 mg/ml of neomycin for 
pBABEneo-BREV5, 100 µg/ml of hygromycin for pBABEhygro-BRE. Two weeks later, 
many cells died, leaving only antibiotic-resistant cells alive. Antibiotic-resistant cells were 
expanded into large cultures in medium without antibiotic. When cells were around 80-90% 
confluent, retrovirus-containing supernatant was harvested and filtered. It was used directly or 
stored at -80ć. 
 
2.2.10.2 Retrovirus concentration 
Retrovirus is usually produced at low titer. It often needs to be concentrated for storage or 
further applications. To concentrate virus, using PEG (Polyethylene glycol) is a convenient 
and timesaving method without ultra-centrifugation. Ten ml of sterile PEG solution (40% PEG, 
2.4% NaCl) was added to 40 ml of the filtered retrovirus-containing supernatant in a 50 ml 
tube. This tube was rotated on a rolling platform at 4ć overnight. After overnight rotation, 
retrovirus was pelleted by centrifuge at 3500 rpm at 4ć for 90 min. Supernatant was 
removed completely. Pellet was resuspended in 400 µORIPBS. One hundred µORI
retrovirus-containing PBS was allocated to four eppendorfs each. This concentrated retrovirus 
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was used directly or stored at -80ć. 
 
2.2.10.3 Retrovirus titering 
Two hundred thousand NIH3T3 cells per well were seeded in six wells of a 6-well plate. 
Around 16 hours later, a serial dilutions (five 10-fold dilutions) of retrovirus in culture 
medium containing 8 µg/ml of polybrene were prepared. Polybrene (hexadimethrine bromide) 
is a cationic polymer used to increase the efficiency of infection of cells with a retrovirus in 
cell culture. Polybrene acts by neutralizing the charge repulsion between virions and sialic 
acid on the cell surface (228). These five 10-fold dilutions were used to infect five wells of 
NIH3T3 cells, respectively. Cells without retrovirus infection were negative control. After 24 
hours infection, 1/20 of cells of each well were splitted onto a 10-cm plate. One day later, 
cells were selected according to the selectable marker of the retroviral expression vector 
(Table 2-20). Five µg/ml of puromycin was used for pBABEpuro-BRE, pBABEpuro-BREV5 
and pBABEpuro-V5BRE, 2 mg/ml of neomycin for pBABEneo-BREV5, 100 µg/ml of 
hygromycin for pBABEhygro-BRE. Around 10 days later, antibiotic resistant cells formed 
several colonies. The cells of negative control were all dead. 
 
Number of colonies was counted on one of the 10-cm plate, which had ten to fifty evenly 
distributed colonies. 
Titer (CFU/ml) = number of colonies / (virus volume × replication factor × fraction of 
infected cell plated) 
Beside, after titer assay, antibiotic resistant NIH3T3 cells were harvested for Western blot 
analysis to confirm the gene of BRE in the retrovirus. 
 
2.2.10.4 Retrovirus transduction 
Ten thousand cells of C6 were seeded in one well of a 6-well plate. Around 16 hours later, 2 × 
10
5
 CFU retrovirus of pBABEneo-BREV5 was used to infect the cells in 8 µg/ml of 
polybrene. After 24 hours infection, cells were trypsinized and resuspended in 24 wells of a 
24-well plate. One day later, cells were selected by 2 mg/ml of neomycin. Around 10 days 
later, neomycin-resistant cells in each well of the 24-well plate were trypsinized and 
resuspended in one well of a 6-well plate. The concentration of neomycin in the medium was 
halved to 1 mg/ml at the same time. Cells were trypsinized when they were around 80-90% 
confluent. Half-cells were used for Western blot analysis, half-cells were kept growing. 
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2.2.11  BRE containing adenovirus generation and 
transduction 
2.2.11.1 Adenovirus generation 
2.2.11.1.1 Subclone BRE into a adenoviral shuttle vector, 
pAdTrack-CMV 
AdEasy technology system was used to generate adenovirus. Three pAdTrack-CMV-based 
adenoviral shuttle vectors containing gene of BRE were generated according to a standard 
molecular cloning procedure. 
 
Table 2-21. Shuttle vectors 






pAdTrack-CMV-BREV5  BRE tagged by V5 at the C-terminus Kanamycin 
pAdTrack-CMV-V5BRE BRE tagged by V5 at the N-terminus Kanamycin 
 
2.2.11.1.2 Generation of recombinant adenovirus plasmids 
(1) Characterization of the pAdEasy®-1 plasmids in AdEasier®-1 cells with extensive 
restriction digestions 
AdEasier®-1 bacterial cells are BJ5183 derivatives, which already contain the supercoiled 
backbone vector, pAdEasy®-1. As BJ5183 cells have a relatively high frequency of 
homologous recombination, unwanted or detrimental rearrangement and/or recombination of 
the pAdEasy®-1 sequences in AdEasier®-1 cell can occur. Thus, it is important for 
characterizing the pAdEasy®-1 plasmids in AdEasier®-1 with extensive restriction digestions. 
Plasmids in AdEasier®-1 cells and pAdEasy®-1 stock DNA, which was made in a strain 
incapable of homologous recombination, were digested by Hind III and Pst IThe digestion 
patterns of these two plasmids were the same. Thus, the unwanted or detrimental 
rearrangement and/or recombination of the pAdEasy®-1 did not occur.  
 
(2) Preparation of electro-competent AdEasier®-1 cells 
Frozen stock of AdEasier®-1 cells was inoculated into 10 ml of LB medium with 100 µg/ml 
of ampicillin in a 50 ml tube. Cells were incubated in a shaker at 37ćovernight. One ml of 
bacterial culture was diluted into 1000 ml of LB medium with 100 µg/ml of ampicillin in 
eight 1 liter flasks (125 ml each). They were incubated for 4 to 5 hour with vigorous aeration 
at 37ć, until the absorbance value at 550 nm was around 0.8. This was done by DU® 800 
spectrophotometer. Then bacterial culture was collected in four 250-ml conical centrifuge 
tubes. These tubes were incubated in ice for 1 hour. Cells were pelleted by centrifuging at 
3,000 rpm (2,600 g) at 4ć for 10 min. All of the pellets were washed by resuspending in 
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1000 ml of sterile, ice-cold WB (WB = 10% ultra-pure glycerol, 90% distilled water, v/v). 
Cell suspension was centrifuged at 3,000 rpm (2500 g) at 4ć for 30 min. Then the wash and 
centrifuge steps were repeated once. After that, most of the supernatant was poured roughly. 
Only about 20 ml of supernatant was left. Cells were resuspended in the left 20 ml of 
supernatant and were transferred to a 50 ml tube. Then cells were spinned at 3,000 rpm at 4ć 
for 10 min. All but 3 ml supernatant was pipetted out. Cells were resuspended in left WB in 
the tube. Cell suspension was allocated to 150 eppendorfs (20 µl each), which had been 
pre-chilled at -80°C. These aliquots were stored at -80ć. 
 
(3) Linearization of adenoviral shuttle vector 
The adenoviral shuttle vector pAdTrack-CMV-BREV5 was picked for adenovirus generation. 
The corresponding adenovirus was named as adenovirus-BREV5. A little of 
pAdTrack-CMV-BREV5 bacterial frozen stock was grown in 5 ml of LB containing 50 mg/ml 
of kanamycin in a 15 ml tube in a shaker at 37ɗ at 250 rpm. After overnight shaking, 
plasmids in the bacterial culture were extracted using a Qiagen miniprep kit. Four µg of 
plasmids was linearized by Pme I in 100 µl of digestion solution. One hundred µl of H2O, 100 
µl of 7.5 M ammonium acetate, and 4 µl of pellet paint co-precipitant were added into the 
digestion solution. DNA was extracted with 300 µl of 25:24:1 phenol/chloroform/isoamyl 
alcohol (pH 8.0). Top layer of DNA solution was transferred to a clean tube. DNA was 
precipitated with 600 µl of 100% ethanol by centrifuging for 5 min at 16000 g at room 
temperature. Pellets were washed three times with 70% ethanol to eliminate residual salt. 
Washed DNA pellets were resuspended in 8 µl of H2O. 
 
(4) Electro-transformation 
Eight µl of linearized pAdTrack-CMV-BREV5 was added into an eppendorf containing 20 µl 
of competent AdEasier®-1 cells. The bacteria/DNA mix was incubated in ice for 30 min. It 
was transferred to an ice-cold E.coli pulser cuvette (0.1 cm electrode gap), carefully avoiding 
formation of bubbles. The cuvette was kept in ice for 5 min. The pulse at 2500 V, 200 Ω, and 
25 µF in a Bio-Rad Gene pulser electroporator was delivered to the cuvette. It was kept in ice 
for 5 min. Five hundred µl of sterile LB medium was added into it. The transformation mix 
was resuspended and transferred into a new eppendorf. The eppendorf was incubated at 250 
rpm for 1 hour at 37ć. Then all of the transformation mix was spreaded into one LB plate 
with 50 mg/ml of kanamycin. The plate was incubated overnight in a 37ć incubator. 
 
(5) Identification of the correct recombinants 
There were five kanamycin resistant colonies on the plate. DNA of these five colonies was 
prepared using a Qiagen miniprep kitDQG digested by Pac I. After digesting the recombinant 
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with Pac I, correct recombinant should yield a large fragment (approximately 30 kb) and a 
small fragment of 3.0 kb or 4.5 kb. The reason of the two possible small fragments is that the 
homologous recombination can occur between two ori regions or two homologous left arms 
on pAdTrack-CMV-BREV5 and pAdEasy®-1, respectively. In my case, after Pac I digestion 
check, two possible correct recombinants, which yielded a smaller fragment of 3.0 kb and 4.5 
kb separately, were picked out among the five kanamycin resistant colonies. The one, which 
yielded a smaller fragment of 3.0 kb, was used for later adenovirus generation. This colony 
was named as recombinant 3. 
 
(6) Re-transformation of recombinant 3 into a recombination-defective strain 
Because of the high frequencies of recombination and rearrangement of large plasmids in 
BJ5183 cells, after checking by the Pac I restriction endonuclease digestion, the recombinant 
3 was re-transformed into a recombination-defective strain (DH5α) by heat shock 
transformation. The re-transformed plasmids in DH5α were digested again by Pac I. They still 
yielded a large fragment (approximately 30 kb) and a small fragment of 3.0 kb. 
 
2.2.11.1.3 Generation of recombinant adenovirus in HEK293T 
packaging cells 
Recombinant 3 was digested with Pac I in 100 µl of digestion solution. One hundred µl of 
H2O, 100 µl of 7.5 M ammonium acetate and 600 µl of 100% ethanol were added into it. This 
mix was incubated at -20ć for 2 hours. DNA was precipitated by centrifuging for 10 min at 
16000 g. Pellets were washed three times with 70% ethanol to eliminate residual salt. Washed 
DNA pellets were resuspended in 20 µl of EB buffer. Purified linearized recombinant 3 was 
transfected to HEK293T cells on a 25-cm
2
 tissue culture flask using Lipofectamine 2000. The 
transfected cells were maintained in 37ć, 5% CO2 incubator for two weeks. One to two ml of 
fresh complete DMEM was added into the flask every 3 days. Since pAdTrack-CMV-BREV5 
contained a GFP monitor, the green fluorescence was observed under fluorescence 
microscopy. The obvious GFP plaques were observed under fluorescence microscopy from 4 
days after transfection. 
 
Around 2 weeks after the transfection, HEK293T cells were harvested from flask by rinsing. 
Cells were centrifuged at 750 rpm for 5 min. All but 2 ml medium was removed. Pellets were 
resuspended by vortex and transferred into two eppendorfs (1 ml each). Four 
freeze-thaw-vortex cycles were performed to release adenovirus from cells. Cells were froze 
in liquid nitrogen bath, thawed in a 37 ć water bath, and mixed by vigorous vortex for 30 
sec. Three more cycles of the freezing-thawing-vortex were repeated. 
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2.2.11.1.4 Stepwise amplification  
(1) The first round of amplification 
One day before infection, HEK293T cells were seeded in two 25-cm
2
 tissue culture flasks 
(approximately 3×106 cells per flask in 7 ml of complete DMEM). After 16 hours incubation, 
cells in each flask with 80-90% confluence were infected by 50% of the primary transfection 
viral supernatant (i.e., 1.0 ml of viral lysate per flask). Usually at 4 days after infection, 50% 
of the infected cells were detached. Cells were rinsed off and transferred into a 50 ml tube. 
Cells were almost all GFP positive at this moment. Cells were centrifuged at 750 rpm for 5 
min. All but 4 ml medium was removed. Pellets were resuspended by vortex. Four 
freeze-thaw-vortex cycles were performed to release adenovirus from cells. 
 
(2) The second round of amplification 
One day before infection, HEK293T cells were seeded in two 75-cm
2
 tissue culture flasks 
(approximately 6×106 cells per flask in 15 ml of complete DMEM). After 16 hours 
incubation, cells with 90% confluence in each flask were infected by 2 ml of viral lysate. Four 
days after infection, 50% of the infected cells were detached. Cells were rinsed off and 
centrifuged. Pellets were resuspended in 8 ml of medium. Four freeze-thaw-vortex cycles 
were performed to release adenovirus from cells. 
 
(3) The third round of amplification 
Four 75-cm
2
 tissue culture flasks of HEK293T cell were seeded. Cells in each flask were 
infected by 2 ml of viral lysate. Infected cells were resuspended in 16 ml of medium. Four 
freeze-thaw-vortex cycles were performed. Adenovirus-containing medium was allocated into 
32 eppendorfs (500 µl each). These aliquots were stored at -80ć. 
 
2.2.11.2 Titer assay 
Two hundred thousand NIH3T3 cells per well were seeded in twelve wells of 6-well plate. 
Around 16 hours later, serial dilutions (twelve 10-fold dilutions) of adenovirus were prepared. 
They were used to infect NIH3T3 for 24 hours. GFP positive cells were counted on one of the 
twelve wells, which had one to ten evenly, distributed GFP positive cells. 
Titer (CFU/ml) = number of GFP positive cells / (virus volume × replication factor) 
            = 4 CFU / (10
-10
 ml × 2)  




2.2.11.3 Adenovirus transduction 
Two hundred thousand target cells, such as C6, were seeded in one well of a 6-well plate. 
Four million CFU diluted adenovirus in 3 ml of fresh medium was used to infect the cells. 
After 48 hours infection, cells were harvested for Western blot analysis. 
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CHAPTER 3: BRE attenuates apoptosis through 
maintaining the cellular level of an apoptotic inhibitor 
XIAP 
3.1 Establishment of cell lines with BRE expression stably 
knocked down by shRNA  
BRE is a death receptor-associated protein, which can attenuate extrinsic apoptosis initiated 
by activation of death receptors, TNFR-1 and Fas, and intrinsic apoptosis activated by 
DNA-damaging agents or by the potent protein kinase inhibitor, staurosporine (199, 212). In 
vivo anti-apoptotic function of BRE has been demonstrated by attenuation of Fas agonist 
antibody-induced acute fulminant hepatitis in transgenic mice over-expressing human BRE in 
the liver. Consistent with the common association of reduced apoptosis with tumorigenesis, 
protein level of BRE is up-regulated in human hepatocellular carcinoma (198). Transgenic 
mice with overexpression of human BRE in the liver showed significantly faster growth of 
diethylnitrosamine-induced liver tumors (216). Despite the functional characterization of BRE 
as an anti-apoptotic protein, and its implication in tumorigenesis, the molecular and 
biochemical mechanisms by which this protein inhibits mitochondrial apoptotic pathway 
remain completely unknown. 
 
To begin addressing the above issues, we have recently generated D122 cell lines with BRE 
expression stably depleted by shRNA. These cell lines are named with the prefix ‘B07’. The 
negative control shRNA stable transfectant lines are named with the prefix ‘T8’. D122 is a 
mouse Lewis lung carcinoma cell line, which we have previously employed to study the effect 
of BRE overexpression on apoptosis, tumor growth, and metastasis (199, 215). As shown, the 
BRE expression in B07 cell lines (Figure 3-1, lane 2, 4, 6, 8) was efficiently knocked down. 







Figure 3-1. Establishment of cell lines with BRE expression stably knocked down by 
shRNA. 
B07 (C3, C6, 15, 22) were independent lines of D122 with stable BRE shRNA transfection. 
T8 (0, 2, 3, 5) were independent lines of D122 with stable empty shRNA vector transfection 
as negative controls. The protein loading was visualized by the GAPDH. This experiment was 























3.2 BRE-depleted cells are more sensitive to apoptosis 
Decreased apoptotic response to TNF-α in the presence of cycloheximide and anti-Fas agonist 
antibody has been observed in Jurkat and HeLa cell lines upon ectopic expression of BRE. By 
contrary, siRNA-mediated depletion of BRE in HeLa rendered the cells more susceptible to 
the above TNF-α treatment (199). BRE overexpression could also lead to attenuation of 
intrinsic apoptosis induced by cycloheximide, 4-nitroquinoline-1-oxide, etoposide, and 
staurosporine (199). 
 
In order to determine whether increased apoptotic response can be detected in the stable 
BRE-depleted cell lines B07 upon treatment with extrinsic and intrinsic apoptotic stimuli, 
B07 and E7, a subclone of B07, together with the parent cell D122 and negative shRNA 
control lines T8 were treated with TNF-α in the presence of cycloheximide (CHX) for 
extrinsic apoptosis, and etoposide for intrinsic apoptosis. When cells were subjected to 
apoptotic stimulation by TNF-α and CHX, the parent cell D122, negative control shRNA 
counterpart T8 showed apoptosis, as indicated by cleavage of PARP and caspase 3, starting 
from 9 hours of the treatment. Apoptosis of B07 and E7 started as early as 5 hours (Figure 3-2, 
A). When cells were subjected to apoptotic stimulation by etoposide, the parent cell D122, 
negative control shRNA counterpart T8 just began to show apoptosis at 16 hours of the 
treatment. In contrast, B07 and E7 already showed strong apoptosis at this time point (Figure 
3-2, B).  
 
Thus, the BRE-depleted cells are more sensitive to apoptosis induced by death receptor 
(Figure 3-2, A) and genotoxic stimulus (Figure 3-2, B) than the non-depleted counterparts, 
parent D122 and negative control shRNA transfectants. This result corroborates the previous 





















Figure 3-2. BRE-depleted cells are more sensitive to apoptosis. 
BRE-depleted cells, B07 and E7, parent D122, and negative shRNA control line, T8, were 
treated with 20 ng/ml of TNF-α in the presence of 10 mg/ml of cycloheximide (CHX) (panel 
A), and 500 µM of etoposide (panel B), respectively. DMSO was used as solvent control. 
After the indicated time duration, cells were harvested for Western blot analysis. Apoptosis 
was indicated by the appearance of cleaved PARP and cleaved caspase 3. Protein loading was 







3.3 BRE-depleted cells are susceptible to TNF-α induced 
apoptosis in the absence of cycloheximide 
In most cell types including D122, apoptotic induction by TNF-α requires concurrent 
inhibition of protein synthesis. This is because activation of TNFR-1 by its ligand TNF-α, 
triggers both pro- and anti-apoptotic signaling pathways, the latter of which functions by de 
novo synthesis of more of the anti-apoptotic proteins through NF-κB activation to counter the 
former (229). Cycloheximide (CHX) is a commonly used inhibitor of protein synthesis when 
TNF-α is used to induce apoptosis. 
 
To determine whether the BRE-depleted cells are susceptible to TNF-α even in the absence of 
cycloheximide, the BRE-depleted cells B07 and E7 together with the parent cell D122 and 
negative shRNA control lines T8 were treated with TNF-α alone for the indicated time 
duration and then harvested for Western blot analysis of apoptosis. Apoptosis was found to 
occur to B07 and E7, but not the non-depleted cells, at 16 and 24 hours of the treatment 
(Figure 3-3). Flow cytometric analysis also revealed apoptosis of B07 but not T8 treated with 
TNF-α alone for 16 and 23 hours (Figure 3-4).  
 
Both of the Western blot and flow cytometric analyses showed that the BRE-depleted cells are 
susceptible to TNF-α even in the absence of cycloheximide, indicating the absence of BRE 
has the same functional consequence as the presence of CHX in TNF-α-induced apoptosis, 
which is the inhibition of the up-regulation of anti-apoptotic proteins by TNFR1-activated 
NF-κB pathway. The next step was therefore to identify if there is any NF-κB-up-regulated 








Figure 3-3. BRE-depleted cells are susceptible to TNF-α induced apoptosis in the absence 
of cycloheximide (Western blot analysis). 
BRE-depleted cells, B07 and E7, parent D122 and negative shRNA control line, T8, were 
treated with 10 ng/ml of TNF-α in the absence of CHX. DMSO was used as solvent control. 
After the indicated time duration, cells were harvested for Western blot analysis. Apoptosis 
was indicated by the appearance of cleaved PARP and cleaved caspase 3. Protein loading was 









Figure 3-4. BRE-depleted cells are susceptible to TNF-α induced apoptosis in the absence 
of cycloheximide (flow cytometric analysis). 
BRE-depleted cells B07 and negative shRNA control line, T8, were treated with 10 ng/ml of 
TNF-α in the absence of CHX. DMSO was used as solvent control. After the indicated time 
duration, cells were harvested for flow cytometric analysis using Annexin V-FITC and 
Propidium Iodide staining. Viable cells were indicated in lower left quadrant; apoptotic cells 


















3.4 Reduction of XIAP in BRE-depleted cells 
The apoptotic susceptibility of the BRE-depleted cells to TNF-α alone suggests the absence of 
some of the anti-apoptotic proteins,which are up-regulated following NF-κB activation. We 
followed this lead to investigate the expression levels of four anti-apoptotic proteins, among 
others, known to be up-regulated following NF-κB activation, cIAP-1, cIAP-2, XIAP, and 
cFLIP (229, 230). Depletion of BRE had no effect on the protein levels of cIAP-1, cIAP-2, 
cFLIPL, and cFLIPS (Figure 3-5, A). However, XIAP protein expression was remarkably 
reduced in the BRE-depleted cells (Figure 3-5, B). 
 
XIAP is the most potent inhibitor of caspases of IAP family. In contrast to cIAP-1, cIAP-2, 
and cFLIP, which inhibit only the extrinsic apoptosis, XIAP inhibits the initiator caspase 9 of 
the intrinsic pathway, as well as effector caspase 3 and 7 common to both of the intrinsic and 
extrinsic pathways (231, 232). Thus, cells depleted of XIAP are expected to be sensitized to 
both of the death receptor ligands, and genotoxic stimuli. This finding fits well to the 































Figure 3-5. Reduction of XIAP in BRE-depleted cells 
(A) Left panel: parent cell D122, BRE-depleted cells B07, negative control T8, together with 
anther cell line HeLa were lysed for Western blot analysis and probed by anti-cIAP-1 antibody. 
Middle panel: BRE-depleted cells B07 and negative control T8 were lysed for Western blot 
analysis and probed by anti-cIAP-2 antibody. Right panel: BRE-depleted cells B07 and 
negative control T8 were lysed for Western blot analysis and probed by anti-cFLIP antibody. 
This experiment was performed once. 
(B) B07 (C3, C6, 15, 22) are independent lines of D122 with stable BRE shRNA transfection. 
T8 (0, 2, 3, 5) are independent lines of D122 with stable empty shRNA vector transfection as 
negative controls. These cells were lysed for Western blot analysis and probed by anti-BRE 
and anti-XIAP antibodies. The protein loading was visualized by GAPDH. This experiment 




3.5 Recovery of BRE restores XIAP in BRE-depleted cells  
Taken the above data together, it is highly likely that I have already identified a molecular 
mechanism for the anti-apoptotic activity of BRE. I hypothesize that BRE through 
maintaining the cellular XIAP level attenuates apoptosis. To test the above hypothesis, BRE 
level was restored via the retrovirus infection in the stable BRE-depleted cell line, C6, which 
is one of B07 cell lines. In C6, the protein level of XIAP, as shown in Figure 3-5, B, was less 
than the parent cell lines D122. However, when the V5-tagged BRE was introduced into C6, 
via the retrovirus transduction, the XIAP level was also restored. The level of XIAP recovery 
was related to the level of BRE expression (Figure 3-6). Thus, it is confirmed that BRE has a 
critical role in maintaining the cellular XIAP level. Next, the issue of whether C6 cells with 


















Figure 3-6. Recovery of BRE restores XIAP in BRE-depleted cells. 
pBABEneo-BREV5 retroviruses were generated by the co-transfection of retroviral 
expression vector pBABEneo-BREV5 and the package vector pCL-Ampho to the package 
cell line HEK293T. The exogenous BRE was tagged by V5 at the C-terminus. The parent cell 
line was mouse Lewis lung carcinoma D122. C6 was a subclone of B07, which was the line 
of D122 with stable BRE shRNA transfection. Clone 2, 3, 6, 9, 10, 11, and 5 were 
independent lines of C6 with stable pBABEneo-BREV5 retrovirus infection, whose BRE 
level were restored at different levels. Clone 9 (asterisked) is unstable with ongoing apoptosis. 

















3.6 Recovery of XIAP or BRE to BRE-depleted cells 
renders the cells less sensitive to TNF-α induced apoptosis 
C6 cells with XIAP or BRE level restored were subjected to apoptotic stimulation by TNF-α. 
While the C6 with empty vector pcDNA3 transfection, showed apoptosis, as indicated by 
cleavage of PARP, starting from 3 hours of TNF-α treatment, apoptosis of the 
XIAP-transfected C6 cells was delayed (Figure 3-7). Similarly, C6 without BRE restoration, 
showed apoptosis, as indicated by cleavage of PARP, starting from 3 hours of TNF-α 
treatment, apoptosis of the BRE-restored counterpart was significantly attenuated (Figure 3-8). 
Taken together, the BRE-depleted cells with BRE level or XIAP level restored are less 















Figure 3-7. Recovery of XIAP to BRE-depleted cells renders the cells less sensitive to 
TNF-α induced apoptosis. 
C6, an independent line of BRE-depleted cells B07, were transfected with the 
pEBB-FLAG-XIAP & pcDNA3, or pcDNA3 alone. In pEBB-FLAG-XIAP, the exogenous 
XIAP was tagged by FLAG. The pcDNA3 alone transfected cells were used as negative 
control. Forty-eight hours after transfection, the culture mediums of the cells were changed to 
fresh mediums containing 10 ng/ml of TNF-α. DMSO was used as solvent control. After the 
indicated time duration, cells were harvested for Western blot analysis. Since C6 is a stable 
BRE-depleted cell line, the endogenous BRE of could not be detected by our anti-BRE 
antibody. When C6 was transfected with pEBB-FLAG-XIAP & pcDNA3, both the 
FLAG-tagged and endogenous XIAP could be detected by the anti-XIAP antibody (lane 5-8). 
Apoptosis was indicated by the appearance of cleaved PARP. Protein loading was visualized 




Figure 3-8. Recovery of BRE to BRE-depleted cells renders the cells less sensitive to 
TNF-α induced apoptosis. 
C6, an independent line of BRE-depleted cells B07, was transduced with pBABEneo-BREV5 
retrovirus for restoration of BRE and treated with 10 ng/ml of TNF-α. DMSO was used as 
solvent control. After the indicated time duration, cells were harvested for Western blot 
analysis for apoptosis to compare with un-transduced C6 treated likewise. Apoptosis was 
indicated by the appearance of cleaved PARP. Protein loading was visualized by GAPDH. 














3.7 N-Ethylmaleimide (NEM) affects BRE and XIAP 
3.7.1 NEM affects BRE staining by anti-BRE (Mab489-7) 
antibody 
Our team generated the first 2 monoclonal antibodies to BRE, Mab489-7 (IgG1) and Mab246 
(IgG3). Mab489-7 performs better in Western blotting compared with Mab246, whereas 
Mab246 does better in immunohistochemistry and immunoprecipitation (198). I observed that 
when GSB2 cells, Jurkat A3 with stable GS-BRE (V5-tagged) transfection (199), were lysed 
in buffer containing 20 mM of NEM, both the endogenous and V5-tagged BRE could not be 
detected by Mab489-7 (Figure 3-9, lane 1). However, the endogenous and V5-tagged BRE in 
the same lysate remained detectable by Mab246. The use of anti-V5 antibody also detected 
the V5-tagged BRE. These observations indicate that NEM abolished the binding between 
BRE and Mab489-7, but not BRE protein level. It should be noted that both Mab489-7 and 
Mab246 were generated by using a human BRE protein fragment from residues 40 to 225 as 
the immunogen (198). This peptide contains five cysteine residues, which NEM can 
irreversibly bind through formation of a strong thioester bond, resulting in changes of local 
structure. Mab489-7, but not Mab246, may bind to the NEM-sensitive epitope, which 
contains or is proximal to cysteine. Next, because of the association between BRE and XIAP 






Figure 3-9. NEM affects BRE staining by anti-BRE (Mab489-7) antibody. 
The cells were GSB2 (Jurkat A3 with stable GS-BRE transfection), expressing both of the 
endogenous BRE and exogenous BRE tagged by V5 at the C-terminus. Two types of fresh 
lysis buffer with or without 20 mM of NEM were used to lyse the cells. The lysates were 
probed by anti-BRE (Mab489-7), anti-BRE (Mab246), HRP-anti-V5, and anti-GAPDH 
antibodies. This experiment was performed in triplicate. 
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3.7.2 NEM affects XIAP 
In this set of experiments, cell lysates were first prepared with lysis buffer containing no 
NEM, which was subsequently added to the cell lysates. Again, recognition of BRE by 
anti-BRE antibody (Mab489-7) was reduced (Figure 3-10, lane 3-5). Furthermore, XIAP level 
in the cell lysate, immunoblotted by anti-XIAP antibody, was also reduced. This could be 



















Figure 3-10. NEM affects XIAP. 
The cells were GSB2 (Jurkat A3 with stable GS-BRE transfection), expressing both of the 
endogenous BRE and exogenous BRE tagged by V5 at the C-terminus. These cells were lysed 
in the routine lysis buffer first. The same amount of protein (5 µg) was allocated to five 
eppendorfs. NEM was added into three eppendorfs, making the concentration to be 20 mM, 
39 mM, and 50 mM (lane 3-5). H2O was added as solvent control (lane 2). Eppendorf with 
nothing added into it was negative control (lane 1). They were probed by anti-BRE 
(Mab489-7), HRP-anti-V5, anti-XIAP, and anti-GAPDH antibodies. This experiment was 










3.7.3 NEM reduces XIAP instead of antibody-binding 
failure 
NEM was added to the lysate of HEK293T transfected with pEBB-FLAG-XIAP. As expected, 
this reduced the immunoblot staining signal by Mab489-7, as well as anti-XIAP antibody. Of 
note is that the staining signal by anti-FLAG antibody was also reduced (Figure 3-11 lane 2, 
3). As the amino acid sequence of FLAG epitope, which is DYKDDDDK, contains no 
cysteine. I conclude that the XIAP level in the cell lysate with added NEM was reduced. Since 
the BRE level in the NEM-containing cell lysate remained unchanged, I further propose that 




















Figure 3-11. NEM reduces XIAP instead of antibody-binding failure. 
HEK293T cells were transfected with the pEBB-FLAG-XIAP. In the pEBB-FLAG-XIAP, the 
exogenous XIAP was tagged by FLAG. Forty-eight hours after transfection, these cells were 
lysed in the routine lysis buffer first. The same amount of protein (5 µg) was allocated to four 
eppendorfs. NEM was added into two eppendorfs, making the concentration to be 90 mM 
(lane 2, 3). H2O was added as solvent control (lane 1). Eppendorf with nothing added into it 
was negative control (lane 4). They were probed by anti-BRE (Mab489-7), HRP-anti-FLAG, 















3.8 Ubiquitination of XIAP is important for its stability  
3.8.1 VAD cannot preserve XIAP upon 16 hours of 
etoposide treatment 
From the above data, BRE can maintain cellular level of the anti-apoptotic protein XIAP. 
However, the mechanism is unknown. This set of experiments was carried out to identify the 
mechanism. The cell line used was GSV1 (Jurkat A3 with stable empty vector pcDNA3.1/GS 
transfection). GSV1 cells were treated with etoposide (intrinsic apoptosis stimulus), and with 
or without VAD (the broad-spectrum caspase inhibitor) for the indicated time duration. Upon 
16 hours of etoposide treatment, the cellular XIAP was decreased to a barely detectable level. 
Inclusion of VAD inhibited the caspase-induced cleavage efficiently, as shown by the 
persistence of un-cleaved PARP during apoptotic stimulation. XIAP is known to be cleaved 
by caspases, which was observed in this experiment. However, inclusion of VAD cannot 
preserve XIAP upon 16 hours of etoposide treatment (Figure 3-12 lane 1, 2). This paradox 
indicates that some other mechanisms, such as the proteasome-mediated degradation, may 










Figure 3-12. VAD cannot preserve XIAP upon 16 hours of etoposide treatment. 
GSV1 cells (Jurkat A3 with stable empty vector pcDNA3.1/GS transfection) were treated 
with 25 µM of etoposide (intrinsic apoptosis stimulus), and with or without 20 µM of VAD 
(the broad-spectrum caspase inhibitor) for the indicated time duration. DMSO treated cells 
were the negative control. After the indicated time duration, cells were harvested for Western 
blot analysis. Both of the full length XIAP and XIAP fragment cleaved by caspases were 
probed by anti-XIAP antibody. Apoptosis was indicated by the appearance of cleaved PARP. 














3.8.2 Degradation of XIAP in response to etoposide in the 
presence of VAD is due to proteasomal degradation 
This experiment was carried out to determine whether the degradation of XIAP during 
apoptosis was caused by proteasome-mediated degradation. Cells of GSV1 were treated with 
MG132 (proteasome inhibitor) alone, etoposide alone, etoposide & MG132, etoposide & 
VAD, MG132 & VAD, or etoposide & MG132 & VAD for 16 hours. Inclusion of VAD cannot 
preserve XIAP upon 16 hours of etoposide treatment (Figure 3-13 lane 4), whereas MG132 
can completely rescue XIAP in the presence of VAD (Figure 3-13 lane 6), indicating that the 
degradation of XIAP in response to etoposide in the presence of VAD is due to proteasomal 
degradation. Only the ubiquitin chains labeled proteins can be destroyed via proteasome. Thus, 













Figure 3-13. Degradation of XIAP in response to etoposide in the presence of VAD is due 
to proteasomal degradation. 
GSV1 cells (Jurkat A3 with stable empty vector pcDNA3.1/GS transfection) were treated 
with MG132 alone, etoposide alone, etoposide & MG132, etoposide & VAD, MG132 & VAD, 
or etoposide & MG132 & VAD for 16 hours. The concentrations of etoposide, MG132, and 
VAD were 25 µM, 5 µM, and 30 µM. DMSO treated cells were negative control. After 16 
hours duration, cells were harvested for Western blot analysis. Both of the full length XIAP 
and XIAP fragment cleaved by caspases were probed by anti-XIAP antibody. Apoptosis was 
indicated by the appearance of cleaved PARP. Protein loading was visualized by GAPDH. 









3.9 BRE leads to the removal of or inhibits ubiquitination 
of XIAP 
3.9.1 Immunoprecipitation of ubiquitinated XIAP 
BRE has two UEV domains, which are ubiquitin-binding domains. BRE was found to bind to 
K48- and K63-linked polyubiquitin chains in vitro assay (194). According to the 
above-mentioned result, ubiquitination of XIAP is important for its stability. Thus, I 
hypothesize that BRE maintains the cellular XIAP level by affecting the ubiquitination 
process of XIAP. There are two issues need to be solved: (1) Can BRE affect the 
ubiquitination of XIAP? (2) :hat type of ubiquitination (K48-, K63-, or K0-linked) of XIAP 
can be affected by BRE?  
 
To start, I established a specific and effective system to immunoprecipitate the ubiquitinated 
XIAP. Two immunoprecipitation experiments were carried out. In experiment 1 (Figure 3-14), 
plasmids pEBB-FLAG-XIAP with or without pRK5-HA-Ubiquitin-K48 were transfected to 
HEK293T. In experiment 2 (Figure 3-15), plasmids pRK5-HA-Ubiquitin-K48 with or without 
pEBB-FLAG-XIAP were transfected to HEK293T. pRK5-HA-Ubiquitin-K48 is an expression 
vector containing K48-only ubiquitin with all of the other lysines mutated to arginines. 
Therefore, such mutant can only form poly-ubiquitin chains via K48. In these two 
experiments, exogenous K48-linked polyubiquitinated XIAP, immunoprecipitated by 
anti-FLAG antibody and probed by HRP-anti-HA antibody, only appeared in cells with 
pEBB-FLAG-XIAP and pRK5-HA-Ubiquitin-K48 co-transfection. Taken together, 
overexpressed XIAP undergoes K48-linked polyubiquitination. This immunoprecipitation 
system is specific and effective to immunoprecipitate ubiquitinated XIAP. Thus, this system 




Figure 3-14. Immunoprecipitation of ubiquitinated XIAP, experiment 1 
HEK293T cells were transfected with pEBB-FLAG-XIAP with or without 
pRK5-HA-Ubiquitin-K48. HEK293T cells without any transfection were used as negative 
control. Forty-eight hours after transfection, cells were harvested for immunoprecipitation. 
Anti-FLAG antibody (F3165, Sigma) was used to pull down FLAG-tagged XIAP. 
Anti-Mouse (G3A1) IgG1 Isotype Control (#5415S, Cell Signaling) was used as negative 
control. Immunoprecipitated samples together with the whole lysate were probed by 
HRP-anti-FLAG (A8592, Sigma), HRP-anti-HA (H6533, Sigma), and anti-GAPDH 




Figure 3-15. Immunoprecipitation of ubiquitinated XIAP, experiment 2 
HEK293T cells were transfected with pRK5-HA-Ubiquitin-K48 with or without 
pEBB-FLAG-XIAP. HEK293T cells without any transfection were used as negative control. 
The later steps were the same with immunoprecipitation of ubiquitinated XIAP, experiment 1. 






3.9.2 BRE leads to the removal of or inhibits endogenous 
ubiquitination of XIAP 
This experiment was carried out to identify whether BRE affects ubiquitination of XIAP. 
Plasmids pEBB-FLAG-XIAP with or without pEBB-FLAG-BRE were transfected to 
HEK293T. Ubiquitinated XIAP, pulled down by anti-XIAP antibody, was probed by 
biotinylated anti-XIAP and anti-ubiquitin antibodies. As shown, the biotinylated anti-XIAP 
antibody was more sensitive than anti-ubiquitin antibody to detect polyubiquitin of XIAP. Of 
note, the ubiquitinated XIAP formed smear was less when BRE was included. This difference 
was more obvious when biotinylated XIAP was used for probe (Figure 3-16). This data 
indicates that BRE leads to the removal of or inhibits ubiquitination of XIAP. Thus, the next 







Figure 3-16. BRE leads to the removal of or inhibits endogenous ubiquitination of XIAP. 
HEK293T cells were transfected with pEBB-FLAG-XIAP with or without pEBB-FLAG-BRE. 
Forty-eight hours after transfection, culture medium was changed into fresh medium 
containing 5 µM of MG132. Two hours later, cells were harvested for immunoprecipitation. 
Anti-XIAP antibody (610717, BD) was used to pull down endogenous and exogenous XIAP. 
Anti-Mouse (G3A1) IgG1 Isotype Control (#5415S, Cell Signaling) was used as negative 
control. Immunoprecipitated samples together with the whole lysate were probed by 
biotinylated anti-XIAP (BAF8221, R&D), anti-ubiquitin (550944, BD), and anti-GAPDH 
antibodies. Lysate was also probed by anti-BRE and anti-PARP antibodies. The asterisked 
band around 55 kDa was heavy chains of anti-Mouse (G3A1) IgG1 Isotype Control. This 
experiment was performed once. 
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3.9.3 BRE does not affect exogenous K48-linked 
ubiquitination of XIAP 
To explore the type of ubiquitination (K48-, K63-, or K0-linked) of XIAP that can be affected 
by BRE, the major K48-linked polyubiquitination, which labels proteins for degradation by 
proteasome, was investigated first. Plasmids pEBB-FLAG-XIAP and 
pRK5-HA-Ubiquitin-K48, with or without pEBB-FLAG-BRE were transfected to HEK293T. 
pRK5-HA-Ubiquitin-K48 is an expression vector containing K48-only ubiquitin with all of 
the other lysines mutated to arginines. Therefore, such mutant can only form poly-ubiquitin 
chains via K48. Exogenous K48-linked ubiquitinated XIAP, pulled down by anti-XIAP 
antibody, was probed by biotinylated anti-XIAP and HRP-anti-HA antibodies. Of note, the 
K48-linked ubiquitination of XIAP was the same regardless of co-transfection with BRE or 
not (Figure 3-17). Thus, although BRE can bind to K48-linked polyubiquitin chains in vitro, it 





Figure 3-17. BRE does not affect exogenous K48-linked ubiquitination of XIAP. 
HEK293T cells were transfected with pEBB-FLAG-XIAP and pRK5-HA-Ubiquitin-K48, 
with or without pEBB-FLAG-BRE. HEK293T cells without any transfection were negative 
control. Forty-eight hours after transfection, culture medium was changed into fresh medium 
containing 5 µM of MG132. Four hours later, cells were harvested for immunoprecipitation. 
Anti-XIAP antibody (610717, BD) was used to pull down endogenous and exogenous XIAP. 
Anti-Mouse (G3A1) IgG1 Isotype Control (#5415S, Cell Signaling) was used as negative 
control. Immunoprecipitated samples together with the whole lysate were probed by 
biotinylated anti-XIAP (BAF8221, R&D), HRP-anti-HA (H6533, Sigma), and anti-GAPDH 
antibodies. Lysate was also probed by anti-BRE and anti-PARP antibodies. This experiment 
was performed in duplicate. 
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3.9.4 BRE does not affect exogenous K63-linked 
ubiquitination of XIAP 
BRE can also bind K63-linked polyubiquitin chain in vitro (194), so this type of ubiquitin 
chain for XIAP was investigated next. Plasmids pEBB-FLAG-XIAP and 
pRK5-HA-Ubiquitin-K63, with or without pEBB-FLAG-BRE were transfected to HEK293T. 
pRK5-HA-Ubiquitin-K63 is an expression vector containing K63-only ubiquitin with all of 
the other lysines mutated to arginines. Therefore, such mutant can only form poly-ubiquitin 
chains via K63. Exogenous K63-linked ubiquitinated XIAP, pulled down by anti-XIAP 
antibody, was probed by both of biotinylated anti-XIAP and HRP-anti-HA antibodies. Of note, 
as with the K48-linked ubiquitination, K63-linked ubiquitination of XIAP was not affected by 
co-transfection with BRE (Figure 3-18). Thus, although BRE can bind to K63-linked 








Figure 3-18. BRE does not affect exogenous K63-linked ubiquitination of XIAP. 
HEK293T cells were transfected with pEBB-FLAG-XIAP and pRK5-HA-Ubiquitin-K63, 
with or without pEBB-FLAG-BRE. HEK293T cells without any transfection were negative 
control. Forty-eight hours after transfection, culture medium was changed into fresh medium 
containing 5 µM of MG132. Two hours later, cells were harvested for immunoprecipitation. 
Anti-XIAP antibody (610717, BD) was used to pull down endogenous and exogenous XIAP. 
Immunoprecipitated samples together with the whole lysate were probed by biotinylated 
anti-XIAP (BAF8221, R&D), HRP-anti-HA (H6533, Sigma), and anti-GAPDH antibodies. 
Lysate was also probed by anti-BRE and anti-PARP antibodies. This experiment was 
performed in duplicate. 
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3.9.5 BRE leads to the removal of or inhibits exogenous 
K0-linked ubiquitination of XIAP 
Linear ubiquitin chains are those linked via the C- and N-terminus of ubiquitins without 
involving any lysine residue of the ubiquitin. To investigate if head-to-tail linear 
ubiquitination occurs to XIAP, and whether the ubiquitination could be affected by BRE, 
plasmids pEBB-FLAG-XIAP and pRK5-HA-Ubiquitin-K0, with or without 
pEBB-FLAG-BRE were transfected to HEK293T. pRK5-HA-Ubiquitin-K0 is an expression 
vector containing K0 ubiquitin with all of the lysines mutated to arginines. Therefore, such 
mutant can only form head-to-tail linear poly-ubiquitin chains without involving any lysine 
residue. The K0-linked ubiquitinated XIAP, pulled down by anti-XIAP antibody, was probed 
by biotinylated anti-XIAP and HRP-anti-HA antibodies. Of note, inclusion of BRE led to 
weaker and shorter K0-linked ubiquitination of XIAP, indicating that overexpression of BRE 








Figure 3-19. BRE leads to the removal of or inhibits exogenous K0-linked ubiquitination 
of XIAP. 
HEK293T cells were transfected with pEBB-FLAG-XIAP and pRK5-HA-Ubiquitin-K0, with 
or without pEBB-FLAG-BRE. HEK293T cells without any transfection were negative control. 
Forty-eight hours after transfection, culture medium was changed into fresh medium 
containing 5 µM of MG132. Two hours later, cells were harvested for immunoprecipitation. 
Anti-XIAP antibody (610717, BD) was used to pull down endogenous and exogenous XIAP. 
Immunoprecipitated samples together with the whole lysate were probed by biotinylated 
anti-XIAP (BAF8221, R&D), HRP-anti-HA (H6533, Sigma), and anti-GAPDH antibodies. 
Lysate was also probed by anti-BRE and anti-PARP antibodies. This experiment was 
performed in duplicate. 
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CHAPTER 4: Discussion 
4.1 Summary 
Here I report identification of the molecular and biochemical mechanisms by which BRE 
inhibits apoptosis. BRE carries out its anti-apoptotic function through maintaining the cellular 
level of XIAP, which is a potent endogenous inhibitor of apoptosis. To start, we established a 
cell line of mouse Lewis lung carcinoma D122 with BRE expression stably depleted by 
shRNA. The BRE-depleted cells were indeed more sensitive to apoptosis induced by death 
receptor (TNF-α in the presence of cycloheximide (CHX)) and genotoxic (etoposide) stimuli 
than the parent and negative control shRNA counterpart. CHX plays a critical pro-apoptotic 
role by inhibiting synthesis of anti-apoptotic proteins, which TNF-α also up-regulates through 
activation of NF-κB pathway. However, BRE-depleted cells were susceptible to 
TNF-α-induced apoptosis even in the absence of CHX, indicating the absence of some of the 
anti-apoptotic proteins, which were up-regulated following NF-κB activation. We followed 
this to investigate the expression level of the NF-κB-driven and CHX-sensitive anti-apoptotic 
proteins. We observed only XIAP, but not cIAP-1, cIAP-2, or cFLIP, was down-regulated in 
BRE-depleted cells. Highly homologous human BRE was reconstituted in BRE-depleted 
mouse cells via retrovirus transduction. Correspondingly, cellular XIAP was also restored. 
Furthermore, reconstitution of the BRE-depleted mouse cells with human BRE or XIAP 
rendered the cells less sensitive to TNF-α-induced apoptosis. Addition of NEM, which binds 
irreversibly to cysteine residues of proteins, to cell lysates, was found to abrogate the 
recognition of BRE by our anti-BRE antibody (Mab489-7) in Western blot analysis. At the 
same time, cellular XIAP in the lysate (determined by anti-XIAP and anti-FLAG antibodies) 
was also found reduced. This correlation provides in vitro evidence that BRE has a protective 
role for XIAP, and that this role is related to cysteine residues of BRE. All of the 
above-mentioned results provide evidence that BRE maintains the cellular level of XIAP to 
exert its anti-apoptotic function. I also explore the mechanism by which BRE stabilizes XIAP. 
The caspase inhibitor VAD cannot preserve XIAP by 16 hours of etoposide treatment, while 
the proteasome inhibitor MG132 can completely rescue XIAP in the presence of VAD, 
indicating that, apart from caspases cleavage, proteasome-mediated degradation of XIAP is an 
important regulatory mechanism for its stability. BRE contains two polyubiquitin-binding 
UEV domains and forms complexes (BRCA1-A and BRISC) with deubiquitination activity. 
Polyubiquitination of endogenous and ectopically expressed XIAP as shown in Western blot 
using anti-ubiquitin antibody, was less when BRE was ectopically expressed. While 
over-expressed XIAP was found to undergo K48-linked, K63-linked, and K0-linked 
polyubiquitination, only the K0-linked one was affected by ectopic expression of BRE. 
Overexpression of BRE led to weaker and shorter K0-linked polyubiquitination of XIAP. 
Thus, removing or inhibiting polyubiquitination of XIAP, at least the head-to-tail linear-linked 
polyubiquitination, may be the mechanism by which BRE stabilizes XIAP. On the other hand, 
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it is possible that, as the HA-tagged Ubiquitin-K0 can be conjugated to and therefore label 
any lysine-linked ubiquitin chains as a terminal non-extendable ubiquitin, the observed 
change in the staining signal of anti-HA antibody in relation to BRE overexpression could 
reflect the activity of BRE on other lysine-linked ubiquitination, not necessarily the 
head-to-tail non-lysine-linked linear ubiquitination. However, such possibility is not likely to 
be true, in view of the above finding that the two major forms of ubiquitin chains, the K48- 
and K63-linked ones, are not affected by ectopic expression of BRE.  
 
4.2 Shortcoming and improvement in future experiment 
To delineate unequivocally the linkage-specificity of BRE on ubiquitinated XIAP, future 
experiments can be done using endogenous ubiquitin-depleted cell lines transfected with 
different type of mutants of ubiquitin. The lethal effect of depleting ubiquitin in cells can be 
resolved by a recently devised tetracycline-inducible RNAi system (233, 234). Three types of 
mutants of ubiquitin can be used. The first type is lysine (K) only mutant, such as K48, K63, 
K6, K11, K27, K29, and K33 ubiquitin, it can only form poly-ubiquitin chains with other Ub 
molecules via that single lysine, since all of other lysines are not present (235). The second 
type is lysine (K) to arginine (R) mutant, such as K48R, K63R, K6R, K11R, K27R, K29R, 
and K33R ubiquitin; it renders Ub unable to form multi-ubiquitin chains via that specific 
lysine with other Ub molecules. However, these proteins can still be linked to the lysine 
residues on target proteins formed via the remaining Ub lysine residues that have not been 
mutated. Thus, these K-to-R mutants can abolish formation of a specific lysine-linked 
ubiquitin chain (235). The third type is K0 ubiquitin, with all of the lysines mutated, enables 
the ubiquitin to only form linear chains via the C- and N-terminus. Transfection of XIAP, with 
or without BRE, to these cells, would unambiguously demonstrate the type(s) of 
ubiquitination that can occur to XIAP, and regulated by BRE.  
 
To demonstrate the hypothesis that removing or inhibiting polyubiquitination of XIAP is the 
mechanism by which BRE stabilizes XIAP. There should be an experiment, which directly 
shows the relationship between the biological half-life of XIAP and ubiquitination of XIAP. To 
observe the half-life of a certain protein, protein synthesis inhibitor, such as cycloheximide 
(CHX), is often used to inhibit the newly synthesized protein. However, when we used CHX to 
treat cells at different time-point, the CHX also induced apoptosis, which triggered XIAP 
degradation. In further experiment, we can try other protein synthesis inhibitors, to solve this 
defect. 
 
Furthermore, in future experiments where the effects on ubiquitination with and without BRE 
transfection are to be compared, an empty vector should be included to make up for the BRE 
expression plasmid in the latter to keep the total amount of plasmids for transfection the same 
as the former for better comparison. 
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4.3 Significance of the research findings 
XIAP is a potent endogenous inhibitor of apoptosis. BRE is found to attenuate both the 
extrinsic and intrinsic apoptosis. Here, my report is the first to demonstrate the positive 
regulatory role of BRE on XIAP protein expression. Caspases are effectors of apoptosis. 
XIAP can inhibit caspase 3, caspase 7, and caspase 9 by direct binding or ubiquitination. 
XIAP also executes its anti-apoptotic function by regulating NF-κB. On the other hand, 
NF-κB induces the expression of XIAP. Thereby, XIAP promotes NF-κB activation in a 
positive feedback loop. Taken together, XIAP is a potent negative regulator of apoptosis in 
caspase-dependent and caspase-independent cell death pathways. Thus, how the cellular level 
of this protein is maintained is pivotal to cell survival. My data show that XIAP is not only 
cleaved by caspases during apoptosis, but also subjected to proteasomal degradation. 
Ubiquitination of XIAP can be catalyzed by the E3 ligase activity of the RING finger itself 
(46) The auto-ubiquitination sites of XIAP are localized to Lys311, Lys322, and Lys328 on 
the BIR3 domain (236). Modification of these sites to arginine dramatically reduces 
ubiquitination of XIAP, but has little effect on the ability of ectopically expressed XIAP to 
rescue cells from two independent apoptotic inducers (Bax and Fas) (236), suggesting that 
auto-ubiquitination of XIAP may have a minimal effect on XIAP protein levels. Recent studies 
show that ubiquitination of XIAP can be catalyzed by some other RING-bearing E3 ubiquitin 
ligases, such as cIAP-1 (90, 91), Siah-1 (seven in absentia homolog 1) (237), and TRIM32 
(238). However, how XIAP ubiquitination is regulated physiologically remains elusive. Many 
antagonists of XIAP have been found. Instead of regulating ubiquitination of XIAP, these 
antagonists predominantly function by steric occlusion of the domains utilized by XIAP to 
bind caspases (83, 110, 239). Notably, the well-known antagonist Smac binds with high 
affinity to XIAP, cIAP-1, and cIAP-2 but stimulates the E3 ligase activity and degradation 
only of cIAP-1 and cIAP-2, suggesting that XIAP ubiquitination may be regulated differently 
(240). Recently, a negative regulator of XIAP, ARTS, has been found to interacts with the E3 
ligase Siah-1 to induce ubiquitination and degradation of XIAP (237). Here, I identify a 
positive regulator of XIAP, BRE, which stabilizes the cellular level of XIAP. Furthermore, 
this kind of stabilization may be exerted by removing or inhibiting the ubiquitination of XIAP. 
At first, I assumed that this type of ubiquitination was K48-linked, since K48-linked chains 
are well established as mediators of proteasomal degradation. However, according to the 
result, BRE removes or inhibits linear ubiquitination, but not K48- or K63-linked 
ubiquitination. This result corresponds with the recently reported finding that the linear type 
ubiquitin also works as a marker for proteasomal degradation by binding with 
ubiquitin-binding domain on the proteasome that recognizes K48-linked ubiquitin chains (241, 
242). Thus, I propose that BRE promotes removal of linear ubiquitin chain of XIAP, or 
inhibition of the chain formation to prevent linear polyubiquitin-mediated proteasomal 
degradation of the protein. The mechanism for such interaction to occur between BRE and 
XIAP requires further investigation. 
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4.4 Possibility of BRE to attenuate apoptosis through 
affecting other NF-κB-activated anti-apoptotic proteins 
Thus far, there are three well-characterized anti-apoptotic families of proteins including cFLIP, 
anti-apoptotic Bcl-2 family members, and inhibitors of apoptosis proteins (IAPs). In my 
experiment, the apoptotic susceptibility of the BRE-depleted cells to TNF-α alone suggests 
the absence of some of the anti-apoptotic proteins, which are up-regulated following NF-κB 
activation. Among the three anti-apoptotic families, cFLIP (243), IAPs (244-246), and three 
anti-apoptotic Bcl-2 family members Bcl-2 (247), Bcl-XL (248), and Bfl1/A1 (249, 250) are 
targets of NF-κB. We only tested the expression level of cFLIP, XIAP, cIAP-1, and c-IAP-2 in 
BRE-depleted cells, revealing only XIAP is down-regulated. However, possible involvement 
of anti-apoptotic member of Bcl-2 family proteins cannot be ruled out. These proteins 
decrease apoptosis mainly by preventing MOMP via neutralizing the activity of pro-apoptotic 
Bcl-2 members (multi-domain members and BH3 only members) (13, 251). The 
non-canonical activity of anti-apoptotic Bcl-2 family member is its ability to regulate cellular 
redox status to prevent excessive build-up of ROS (reactive oxygen species), which is 
detrimental to cells and tissues (251). The possibility of the involvement of promoting 
stability and/or function of anti-apoptotic Bcl-2 family member(s) in anti-apoptotic activity of 
BRE is discussed below. 
 
(1) FKBP38 is a positive regulator of Bcl-2. FKBP38 interacts with the flexible loop domain 
of Bcl-2 directly, preventing Bcl-2 cleavage by caspases, such as caspase 3 and caspase 9 
(252). Furthermore, deregulation of Bcl-2 by ubiquitination is also prevented by FKBP38 
(253). FKBP38 is a FKBP family member. It has four functional domains, including a 
transmembrane motif (TM), a calcium/ calmodulin-binding motif (CaM), a tripartite 
tetratricopeptide repeat (TPR) domain, and a FK506-binding domain (FKBD) (254). The dual 
protective role of FKBP38 to Bcl-2 requires its TPR domain (255). No TPR domain, however, 
has been found in BRE by sequence homology.  
 
(2) Rho is another positive regulator of anti-apoptotic Bcl-2 proteins. Rho inhibition reduced 
expression of anti-apoptotic Bcl-2 and Mcl-1 (256). Rho is a family of small (~21 kDa) 
signaling GTPase. GTPase are hydrolase enzymes that can bind and hydrolyze guanosine 
triphosphate (GTP) (257). The common feature of all GTPases is the highly conserved G 
domain. Three members of Rho family proteins have been studied in detail: Cdc42, Rac1, and 
RhoA (258). No characteristic G domain has been found in BRE by sequence homology.  
 
(3) Beclin 1 is a possible positive regulator of the anti-apoptotic activity of Bcl-2. A proper 
interplay between Beclin 1 and Bcl-2 is responsible for the activity of Bcl-2 in apoptosis 
modulation (259, 260). Besides, Beclin 1 is responsible for the initiation of the formation of 
the autophagosome in autophagy, which is also related with Bcl-2 stabilization (259, 260). 
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There is no homology between BRE and Beclin 1. However, whether BRE is involved in 
autophagy needs further investigation. 
 
(4) Pro-apoptotic BH3-only proteins, including Bad, Bim, Puma, Bid, Bik, Noxa, Hrk, and 
Bmf, are negative regulators of anti-apoptotic Bcl-2 proteins. Protein-protein interactions 
between them occur between the BH3 ‘ligand’ domain in BH3-only proteins and a ‘receptor’ 
BH3-binding groove, formed by BH1-3 regions in the anti-apoptotic Bcl-2 proteins (261, 262). 
To date, whether BRE can inhibit the pro-apoptotic BH3-only proteins has not been reported. 
 
(5) ROS and RNS can regulate Bcl-2 expression levels, thereby impacting its function (263). 
Nitric oxide (NO), one type of RNS, mediates S-nitrosylation of Bcl-2, prevents its 
ubiquitination and subsequent proteasomal degradation, leading to inhibition of apoptosis 
(263). NO is an important signaling molecule, produced endogenously from l-arginine in a 
reaction catalyzed by NO synthases. In contrast, super oxide anion (·O2-), one type of ROS, 
plays a pro-apoptotic role by causing down-regulation and degradation of Bcl-2 protein 
through the ubiquitin proteasomal pathway (263). ROS are byproducts of normal oxygen 
metabolism. However, it is not known whether BRE is involved in the generation or 
regulation of ROS and RNS. 
 
4.5 BRE may function with other deubiquitinase to 
mediate deubiquitination of XIAP 
Deubiquitinases (DUBs) can be divided into five families, UCHs, USPs, OTUs, Josephins, 
and JAMMs. JAMMs are zinc metalloproteases, whereas the other four families are Cys 
proteases (264). The reaction mechanism of Cys proteases is shown in Figure 4-1 (step 1-3) 
and Figure 4-2 (step 4-6) (264-266). During catalysis, a catalytic acyl intermediate is formed 
first, in which the carboxyl group is covalently bound to the catalytic Cys after the amino 
group has been cleaved (step 3, 4). The negatively charged transition state (step 2, 5) is 
stabilized by the nearby oxy-anion hole, which is formed by hydrogen-donating residues. 
Next, a water molecule hydrolyses the acyl-Cys intermediate to release the free DUB and 
ubiquitin (step 6). According to this mechanism, the catalytic Cys is pivotal. The catalytic Cys 
is formed by Cys and another one or two amino acid(s), forming a catalytic diad or triad. A 
nearby His side chain is necessary, which lowers the pKa of Cys. A third residue (usually Asp 
or Asn) is not always necessary. It can polarize and align the His. The mechanism of JAMMs 
is similar to Cys proteases. The difference is that JAMMs utilize a Zn
2+
 bond to polarize water 
(169). The catalytic core domain of DUB, which contains Cys or zinc ion, His, or a third 
residue (Asp or Asn), is conserved in DUB. The consensus sequences of the conserved 
catalytic core domains are shown in Figure 4-3 (174), none of which is present in BRE, 
indicating that BRE itself may not be a DUB. BRE is known to function with DUB, though. 
BRE is important in maintaining the structure and function of two complexes (BRCA1-A and 
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BRISC), which have deubiquitination activity. These two complexes are specific to 
K63-linked polyubiquitin chains due to the BRCC36, which is a JAMM type DUB (200, 201). 
However, in my study, BRE appears to negatively regulate the non-lysine-linked linear 
ubiquitination of XIAP, rather than the K63-linked ubiquitination. Thus, the promotion of 
DUB activity of BRCC36 by BRE may not relevant here.  
 
Among all of the five subtypes of DUBs, JAMMs have a common specificity for K63 
ubiquitin (264). The substrate of UCHs is relatively small protein (up to 20-30 amino acids) 
(174). Thus, I propose that the cooperative DUB of BRE could belong to USP, OTU, or 
Josephin. In vitro analysis shows that some members of USPs, such as IsoT, USP2, USP15, 
and CYLD can cleave linear ubiquitin chains (177). In TNF-α-induced NF-κB signaling 
pathway, both K63 and linear polyubiquitin chains can serve as recruitment platform for 
NEMO, which bridge NEMO with different proteins, thereby promoting IKK activation (147). 
Similarly, K11, K63, and linear polyubiquitin chains can serve as recruitment platform for 
RIP1, which bridge RIP1 with different proteins, resulting in activation of NF-κB (147). 
Recently, USP2 is found to be a positive regulator in this TNF-α-induced NF-κB signaling 
pathway, whereas its target and ubiquitin chains specificity in this pathway has not been 
determined yet (267). USP15 is a negative regulators of this pathway, whereas whether its 
targets involve NEMO and RIP1 needs further investigation (179). CYLD can remove the 
ubiquitin chains from NEMO (178) and RIP1 (179), thereby inactivating NF-κB activation. 
However, whether CYLD can remove the linear ubiquitin chains from NEMO and RIP1 has 
not been reported (179, 180). Two members of OTUs, A20 and TRABID, cannot hydrolyse 
linear chains in vitro. The ability for linear chains of other members of OTUs and Josephins 
has not been reported (177). DUBs are often found as part of large multi-protein complexes. 
The partners of DUB in the complex work to regulate the localization, substrate availability, 
and activity of DUB (268). BRE containing two ubiquitin-binding UEV domains (194) may 
strengthen the ability of DUB in a complex to recognize ubiquitin. Besides, BRE may 
function to sustain the integrity of the deubiquitinating complex, just like in the BRCA1-A 
and BRISC (202). Another possibility is that BRE may directly bridge DUB to XIAP. 
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Figure 4-1. Reaction mechanism for Cys deubiquitinases, step 1-3 (reproduced from 
reference (266))  
C-terminus of ubiquitin is in green. Lys side chain of a linked proximal ubiquitin or substrate 
is in blue. The isopeptide bond is in red. Water molecule is in blue.  
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Figure 4-2. Reaction mechanism for Cys deubiquitinases, step 4-6 (reproduced from 
reference (266))  
C-terminus of ubiquitin is in green. Lys side chain of a linked proximal ubiquitin or substrate 
is in blue. The isopeptide bond is in red. Water molecule is in blue. 
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Figure 4-3. Conserved catalytic core domain of deubiquitinases (reproduced from 
reference (174)) 
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4.6 Comparison of methodologies 
Recently, a E3 ligase complex, LUBAC (linear ubiquitin chain assembly complex) is found to 
results in linear ubiquitination of RIP1 and NEMO and enables the NF-κB pathways to be 
activated (269-271). In general, three types of methods are used to demonstrate that the 
ubiquitin chain is really in head-to-tail conjugation: 
 
(1) In vitro ubiquitination assays 
Reaction mixtures contain E1, appropriate E2, appropriate E3 (LUBAC), and appropriate 
substrate (such as RIP1 or NEMO), are incubated with wide type ubiquitin, methylated 
ubiquitin, different lysine (K) only mutant, such as K48, K63, K6, K11, K27, K29, and K33 
ubiquitin, and linear ubiquitin mutant, separately at 37ć for indicated time in an ATP 
regeneration system. The ubiquitinated substrate is probed by anti-ubiquitin antibody or 
anti-substrate antibody (271). For LUBAC, only the methylated ubiquitin cannot be 
polymerized. The reason is that for linear ubiquitin chains, the isopeptide bond is formed 
between α-amino group of the N-terminal Met of one ubiquitin and the carboxyl group of the 
C-terminal Gly of another (264). Methylation of ubiquitin blocks all of the acceptor sites of 
ubiquitin including Lys and the amino group of the N-terminus, whereas all of the other 
ubiquitins still retain the amino group of N-terminus for linear ubiquitin extension (271). 
 
(2) Mass spectrometry (MS) analysis 
Two types of ubiquitinated substrate (in vivo or in vitro) are generated first. In vitro, 
ubiquitinated substrate is generated by the above-mentioned in vitro ubiquitination 
regeneration system. In vivo ubiquitinated substrate is anti-substrate immunoprecipitates from 
cells, such as HEK293T, co-expressing substrate and E3 (272). These in vivo and in vitro 
ubiquitinated substrate are analyzed using a method combining trypsin digestion and mass 
spectrometry (273, 274). For LUBAC, MS analysis shows that the peptides from 
ubiquitinated NEMO or ubiquitinated RIP1 are only linear linkage (271, 272). 
 
(3) Specific anti-linear ubiquitin antibody analysis 
Recently, a specific antibody against a peptide containing the boundary of head-to-tail-linked 
ubiquitin moieties has been prepared (272). In vivo or in vitro ubiquitinated substrates, as 
described in method (2), are probed by this specific anti-linear ubiquitin antibody to further 
confirm the type of the ubiquitin conjugated to substrate (272). 
Furthermore, in vitro assays for DUB activity for linear ubiquitin chain have also been 
developed. It should be noted that in vivo assay method of such DUB activity is not yet 
available. The procedure of in vitro deubiquitination assay is similar to the above-mentioned 
in vitro ubiquitination regeneration assay. The main difference is that the reactants are 
appropriate DUB and different type of polyubiquitin chains. If DUB is specific to linear 
ubiquitin, this type of polyubiquitin chains will be degraded (177).  
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In my experiment, HEK293T cells were transfected with substrate (XIAP) and HA tagged 
linear ubiquitin, with or without BRE. The ubiquitinated substrate was probed by anti-XIAP 
or anti-ubiquitin antibodies. Comparing with the above-mentioned methods, my method has 
two shortcomings: 
(1) Endogenous ubiquitin may conjugate together with the overexpressed linear ubiquitin. 
(2) The overexpressed linear ubiquitin may not be the same as endogenous linear ubiquitin. 
 
To directly analyze whether endogenous linear ubiquitination of XIAP can be affected by 
BRE, further experiments can be designed as follows: To transfect HEK293T cells with XIAP 
together with or without BRE, which is then followed by immunoprecipitation of 
ubiquitinated XIAP for immunoblotting using specific anti-linear ubiquitin antibody. 
Furthermore, the ubiquitinated XIAP can be analyzed using mass spectrometry. If BRE can 
remove or inhibit the endogenous linear ubiquitin chains of XIAP, the staining intensity of 
anti-linear ubiquitin antibody should be reduced with co-transfection of BRE. MS could also 
be used instead of the anti-linear ubiquitin antibody. Furthermore, to determine whether BRE 
or BRE-containing complex has linear Ub specific DUB activity, an in vitro deubiquitination 
assay, containing linear polyubiquitin chains with purified BRE or BRE over-expressing 
lysate, should be performed. If BRE alone has linear specific DUB activity, the linear 
polyubiquitin chains should be degraded when purified BRE is used. If BRE over-expressing 
lysate instead of purified BRE breaks down linear polyubiquitin chains, then BRE may 
function as a complex in this regard. Besides, BRE may inhibit the formation of linear 
ubiquitination of XIAP. Thus, an in vitro ubiquitination regeneration assay, containing E1, E2, 
E3, substrate (XIAP), linear ubiquitin with or without BRE, can be done to determine whether 
BRE can inhibit the linear ubiquitination formation of XIAP. 
 
4.7 Lysine-linkage specificity of the ubiquitination of 
XIAP 
Ubiquitination of XIAP is important for its stability. However, the exact lysine-linkage 
specificity of the ubiquitination of XIAP has not been examined clearly (232). Ubiquitination 
of XIAP can be catalyzed by itself or by some other RING finger-containing proteins. Some 
factors maintain cellular XIAP level by attenuating the ubiquitination and degradation process. 
These positive regulators include CDK4-binding protein p34
SEI-1
 (275), PGI2 (prostacyclin) , 
Notch (277), and Akt (278). On the other hand, some factors promote XIAP ubiquitination 
and proteasomal degradation. These negative factors include luteolin (279), triterpenoid 
electrophile Avicins (280), and Grim (89). Of note, none of these studies clarified the exact 
lysine-linkage specificity of the ubiquitinated of XIAP, only assuming that it was K48-linked. 
Recently, Nakhaei et al. reported that the lysine-linkage of Sendai virus infection-induced 
auto-ubiquitination of XIAP was K48-linked (281). As mentioned above, BRE promotes 
removal of linear ubiquitin chain of XIAP, or inhibition of the chain formation, to prevent 
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linear polyubiquitin-mediated proteasomal degradation of the protein. My data is not 
necessarily in contradiction with that of Nakhaei et al., since only K48- and K63-linked 
ubiquitination was analyzed in their study. Besides, auto-ubiquitination of XIAP induced by 
Sendai virus infection and other stimuli may result in different lysine-linkage specificities. It 
remains possible that XIAP may undergo linear-linked ubiquitination as proteasomal 
degradation marker for normal protein turnover under non-apoptotic condition, as the 
BRE-depleted cells in which reduction of XIAP occurs is not apoptotic.   
 
4.8 Possibility of BRE to maintain XIAP level utilizing 
other mechanisms  
I have proposed that the attenuation of proteasomal degradation of XIAP may be the 
mechanism by which BRE stabilizes this protein. Could BRE also utilize some other 
mechanisms to maintain cellular XIAP level? I have considered the following:  
 
(1) Protein synthesis regulation  
XIAP synthesis is controlled at the levels of transcription and translation (282). Transcription 
of XIAP is regulated by NF-κB (246). BRE may play a role in NF-κB activation. For example, 
after BRE overexpression, Map3K8 (mitogen-activated protein kinase 8) and TRAF6 (TNF 
receptor P70196 associated factor 6) are found to be up-regulated (283). Map3K8 is able to 
activate NF-κB by stimulating proteasome-mediated proteolysis of NF-κB1/p105 (284). 
TRAF6 is a adapter protein and signal transducer, which links members of the tumour 
necrosis factor receptor family to activation of NF-κB (285). Thus, it is possible for BRE to 
stabilize XIAP by regulating NF-κB. Whether this hypothesis is true requires further 
investigation. Apart from transcription, synthesis of XIAP is also regulated at the level of 
translation. Under normal condition, translation of XIAP is initiated using a 
7-methylguanosine cap-dependent ribosome scanning mechanism, which is the translation 
mechanism for the majority of proteins in eukaryotic cells (286). Under conditions of cellular 
stress and apoptosis, cap-dependent translation is compromised (287, 288). However, 
translation of XIAP mRNA transcript still continues under such condition, relying on the 
cap-independent mechanism (289). This cap-independent translation of XIAP is mediated by 
a 162-nucleotides internal ribosome entry site (IRES) sequence, which is located in the 
5’-untranslated region (UTR) of XIAP mRNA (289, 290). Proteins that modulate IRES 
function, are named as IRES trans-acting factors (ITAFs) (291). The ITAFs of XIAP include 
La autoantigen (289), hnRNP C1/C2 (292), and hnRNP A1 (293). Whether BRE is involved 
in the cap-dependent or cap-independent translation mechanism of XIAP has not been studied 
yet. 
 
(2) Cell cycle-dependent protein expression  
XIAP expression is not cell cycle-dependent (294). One antagonist of XIAP, XAF1, is 
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expressed in a cell cycle-dependent manner. It only expresses in G2/M phase (294). 
BRE-containing complex, BRCA1-A, plays a role in arresting the cell cycle to allow DNA 
repair to take place following DNA damage (200). p53 can induce growth arrest by holding 
the cell cycle at the G1/S phase on DNA damage recognition (295, 296). BRCA1-A might 
exert its cell cycle regulatory function by ubiquitinating p53 via its E3 ubiquitin ligase activity 
(200). After this ubiquitination process, p53 is activated to induce growth arrest (200). BRE is 
important for the cell cycle regulatory function of BRCA1-A. Following DNA damage, 
depletion of BRE and BRCC36 results in defects in G2/M checkpoint (200). Besides, BRE 
might maintain a basal level of cell growth by stabilizing p53 in a transcriptional way (283). 
Furthermore, BRE may regulate other cell cycle regulatory proteins, such as prohibitin, 
Mdm4, and Map3K8 (283). Thus, it is possible for BRE to maintain XIAP in a cell 
cycle-dependent way by attenuating its antagonist XAF1. Whether this hypothesis is true 
requires further investigation. 
 
4.9 Interpretation of NEM-related data 
Addition of NEM was found to abrogate the recognition of BRE by our anti-BRE antibody 
(Mab489-7) in cell lysate. However, the recognition of BRE by our anti-BRE antibody 
(Mab246) or the recognition of V5 tagged BRE by HRP-anti-V5 antibody remained intact in 
the same NEM-containing lysate. Therefore, NEM abolishes the binding between BRE and 
Mab489-7 without affecting BRE protein level. The anti-BRE (Mab489-7) and anti-BRE 
(Mab246) were generated using the human BRE protein fragment from 40 to 225 as 
immunogen (198). This peptide contains five cysteine residues, which NEM can irreversibly 
bind through formation of a strong thioester bond, resulting in changes of local structure. 
Mab489-7, but not Mab246, may bind to the NEM-sensitive epitope, which contains or is 
proximal to cysteine. As the amino acid sequence of V5 epitope, which is 
GKPIPNPLLGLDST, contains no cysteine. Thus, NEM does not interfere with the binding 
between V5 tagged BRE and HRP-anti-V5 antibody. Addition of NEM was found to reduce 
the immunoblotting staining signal by anti-XIAP and anti-FLAG antibodies. As the amino 
acid sequence of FLAG epitope, which is DYKDDDDK, contains no cysteine. Thus, XIAP 
level in the cell lysate with added NEM must also have been reduced. Taken together, addition 
to cell lysate of NEM, which binds to the cysteine residues of BRE, leads to the failure of 
anti-BRE (Mab489-7) to recognize the protein and decline of XIAP level in the same cell 
lysate. This provides in vitro evidence that BRE has a protective role for XIAP, and that this 




Taken together, I have provided evidence that BRE exerts its anti-apoptotic function through 
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maintaining the cellular level of XIAP, a potent endogenous inhibitor of apoptosis. Promoting 
removal of linear ubiquitin chain of XIAP, or inhibition of the chain formation, to prevent 
linear polyubiquitin-mediated proteasomal degradation of XIAP may be the mechanism by 
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To prove the hypothesis that BRE can maintain the cellular XIAP level. We tried to restore 
BRE via adenovirus transduction in the stable BRE-depleted cell line, C6, which is one of 
B07 cell lines. If the hypothesis is true, the cellular XIAP level should also be restored when 
BRE is restored. The adenovirus, which was named as adenovirus-BREV5, was generated by 
a recombinant of pAdTrack-CMV-BREV5 and pAdEasy®-1. It contained the gene of BRE 
tagged by V5 at the C-terminus. After adenovirus transduction, the expression level of ectopic 
V5 tagged BRE was very high. However, this adenovirus induced serious apoptosis in these 

















 Figure 5-1. Adenovirus induces apoptosis in BRE-depleted cells. 
Adenovirus-BREV5 was generated by transfection of a recombinant of 
pAdTrack-CMV-BREV5 and pAdEasy®-1 to the package cell line HEK293T. The ectopic 
BRE in adenovirus-BREV5 was tagged by V5 at the C-terminus. C6 is one of B07 cell lines, 
which are cell lines of D122 with stable BRE shRNA transfection. C6 was infected with 
adenovirus-BREV5 for 48 h. Apoptosis was indicated by the appearance of cleaved PARP. 
Protein loading was visualized by GAPDH. This experiment was performed once. 
 
 
 
